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 In this dissertation, we will explore the interconnectedness between halogen bonds (X-
bonds) and hydrogen bonds in rational biomolecular engineering efforts. As X-bonds are not 
readily designed into biomolecules, we aim to show how they can be advantageous for molecular 
design. We will begin by considering how X-bonds compare to H-bonds and show how the two 
can work in harmony to provide enhanced stabilizing potential. In two unique protein engineering 
efforts we will show 1) how the X-bond can be just as specifying in terms of molecular assembly 
as compared to the H-bond, and 2) how it can coordinate with the H-bond to increase protein 
stability. One study shows the specifying potential the X-bond possesses in terms of coiled-coil 
assembly. While the study points to a direct application of a sensing probe, the scope of the work 
will aid others using coiled-coils for materials purpose, designing protein interfaces or potential 
ligand binding sites. In the other protein engineering study, we will survey how a protein with an 
intrinsically disordered region responds to hydrogen enhanced halogen bond engineering. We 
show how we can drastically increase the thermal stability of the protein through minimal change 
to its primary sequence. This study lends itself to exploring bigger structure-function questions 
and how the stabilizing capacity of halogen bonds fits into this. Through this work we aspire to 
show how useful X-bonds can be for biological engineering efforts by exhibiting their specifying 
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It has long been established that hydrogen bonds (HB) are a crucial part of biology. From 
the structural biology viewpoint, they are involved in protein folding and tertiary structures, ligand 
binding and affinity, DNA base recognition, protein-protein interactions, protein-DNA 
interactions, as well as many others 1. Their strength depends on many factors including 
environment, and the respective donor and acceptor atoms involved in the bond 2. While hydrogen 
bonds are critical for function in naturally occurring systems, one such bond that is not as naturally 
abundant, but behaves quite similarly, is the halogen bond (XB).  
 Halogen bonds date back to the 1800’s, but more recently have influenced crystal 
engineering, metal organic frameworks, and organocatalysis fields 3–5. They are similar in nature 
to hydrogen bonds as they share the same electron-rich Lewis base acceptors, and typically form 
at a distance shorter than the sum of their respective van der Waal radii 6. However, XB donors 
must be halogens (Cl, Br, or I). These electronegative atoms can interact with other electronegative 
atoms (O,N,S) due to the formation of the s-hole on the halogen. This s-hole or electropositive 
crown forms on the halogen as it undergoes s-bond formation with a substituent group. During s-
bond formation, a valence electron on the halogen gets pulled back for the covalent bond, leaving 
an anisotropic charge distribution around the halogen. The partially positive s-hole forms 
diametrically opposed to the s-bond, while a negative ring forms perpendicular to this around the 
belt of the halogen (figure 1.1). As the s-hole is ultimately what drives XB formation, XBs prefer 
a linear geometric dependence, leading to higher specificity. The various halogens and choice of 




Figure 1.1  
Halogen bonds compared to hydrogen bonds and formation of the s-hole. a) The hydrogen bond 
(HB) as it relates to the halogen bond (XB). Hydrogens and halogens form interactions with similar 
electron-rich acceptor atoms (O, N, S). Both of their interaction distances are shorter than the sum 
of the interacting atoms van der Waals radii (SRvdW), and the bonds have an angular dependence. 
The XB forms in a linearly dependent manner as dictated by the s-hole (partially positive region) 
on the crown of the halogen. b) Formation of the s-hole on the halogen. As the unpaired valence 
electron gets pulled back to form the s-bond, a depopulation of electrons occurs coaxially with the 
s-bond, which creates a partially positive region. A partial negative region exists as a belt around 
the halogen perpendicular to the s-bond. This anisotropic charge distribution makes the halogen 
more versatile in terms of potential interactions compared to hydrogen. Figures adapted from Ho 
(2015) 7.   
  
 3 
associated with the interaction. And like the HB, depending on environment and choice of donor 
and acceptor atoms, halogen bonds can vary in strength. However, they are often stronger than 
HB’s, imparting to their use in molecular and biomolecular engineering efforts. One of the few 
naturally occurring halogen bonds (XB) is between the human thyroid receptor and 3,5,3-
triiodothyroxine (T3) 8. The short I --- O distance seen in the structure is evidence that XBs can 
play an important role in terms of ligand recognition.  
 This notion of recognition, specificity, and stability that ensues in XB potential is what has 
drawn many medicinal chemists and pharmaceutical companies to utilize this interaction in small-
molecule therapeutics. Many of the therapeutics that make it through clinical trials and eventually 
get launched contain halogens 9,10. The halogens’ hydrophobic nature allows for easier access 
across lipid bilayers, and the geometrically defined bonds halogens make increase the drug’s 
binding affinity. Both of these aspects lead to more potent therapeutics. As many small-molecule 
medicines bear halogens, pharmaceutical companies are beginning to think about larger 
macromolecules (e.g. biologics - proteins and peptides) as therapeutics. Because they are 
constructed from biological materials, they will have potentially lower toxicity in the cell 
compared to small molecules, and their larger size/surface area allows for more selective binding 
and less off-target effects. A few peptide biologics that have made it to the market include 
calcitonin (32 aa) for osteoporosis and hypercalcemia; teriparatide (34 aa), a parathyroid hormone 
analog; Fuzeon (36 aa) an antiretroviral; and a 41-aa corticotropin releasing hormone 11. The 
market is growing rapidly as the success rate of biologics in the market is about double that of 
small molecules at this point11. As much work still needs to be done in this field, one concept that 
is lacking and could be hugely beneficial to not only pharmaceutical companies, but also biological 
engineers, is how halogens and halogen bonds behave in bigger biological molecules. While much 
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is known about how halogens behave in small-molecule settings, aid in directed organic synthesis, 
and help assemble supramolecular assemblies and metal organic frameworks 9,12,13, the lack of 
quantitative information about them in proteins in particular has prevented their widespread use 
for biological protein engineering efforts (e.g. designing protein interfaces, more stable enzymes 
to carry out reactions, or constructing multivalent proteins).  
From a basic research angle, asking simple questions as to how halogen bonds effect 
protein structure, function, stability, and specificity will be a beneficial initial characterization for 
their exploitation in the challenging realm of protein engineering. A detailed understanding of their 
structure-energy relationship, and especially how the XB compares to its cousin interaction, the 
HB, will be advantageous for future rational design of biomolecules bearing halogens. With this 
in mind, we have elected to study XBs in a peptide-based system (30 aa) and a small partially 
stable protein system (90 aa). These two studies show how XBs can act as specifying and 
stabilizing interactions in protein contexts.  
 As mentioned above, the heart of this work is the investigation of the structure-energy 
relationship, particularly between XBs and HBs engineered into biological systems from an inter- 
and intramolecular perspective. We will specifically look at how XBs compare to more traditional 
HBs as an intermolecular protein-protein interaction and driver of specificity and, how the two 
bonds work together in an intramolecular fashion to increase protein stability. To thoroughly do 
so, the aspects we will be addressing are: (1) How can the HB and XB compete against each other, 
be substituted for each other, and act orthogonal to each other in biological and non-biological 
frameworks? (2) How can the HB enhance the strength of the XB (HBeXB) from an intramolecular 
orthogonal approach? (3) Can we design a sensor probe peptide capable of specifying assembly of 
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a higher order structure through an engineered HB or XB? (4) Can we stabilize an unstable protein 
through HBeXB engineering efforts? 
  We will address the above questions throughout the dissertation in the following manner. 
Chapter 2 will give a more detailed description of the HB and XB, and through examples from the 
PDB and literature, the interplay found between the bonds will be dissected as points of interest 
moving forward in terms of future engineering efforts. Chapter 3 describes the serendipitous 
discovery of the first two purposefully designed systems bearing the Hydrogen Enhanced Halogen 
Bond. Quantum mechanical calculations were done to better understand the inductive effects of 
the hydroxyl group as an ortho, meta, or para director, and how it can behave as an electron 
donating or an electron withdrawing group. Chapter 4 discusses the design and structural and 
thermodynamic characterization of an engineered GCN4 coiled-coil heterotrimer capable of 
assembling through the specific HB or XB electrostatic interaction. Through crystallography, 
differential scanning calorimetry, circular dichroism, and quantum mechanical calculations, it 
delves into the enthalpy-entropy compensation seen between the H and XB and how they compare 
to less specifying hydrophobic interactions. And finally, Chapter 5 addresses the question of can 
the HBeXB increase the stability of a partially stable protein without effecting its overall fold or 
function. Through non-canonical amino acid incorporation of meta-halogenated tyrosines into 
yeast KIX (Kinase Inducible Domain), the in vitro characterization of these engineered proteins is 
carried out via differential scanning calorimetry and circular dichroism. This in vitro study will 
pave the way for these proteins to be explored in vivo.  
 This dissertation describes the interplay that exists between hydrogen and halogen bonds 
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o 2.1 Summary 
 
Non-covalent interactions are some of the most essential interactions when it comes to defining 
how proteins and other macromolecules fold into their tertiary structures. Hydrogen bonds are a 
key component of this group of interactions. Another non-covalent interaction that has been 
recently “re-discovered” is the halogen bond. Similar to the hydrogen bond, it is an electrostatic 
interaction between a partially negative acceptor atom such as O, N, or S in biological systems, 
and a partially positive halogen atom - Cl, Br, and I instead of H. Due to the nature of this bond, it 
has the ability to be stronger and more geometrically defined than a traditional H-bond, thus 
making it potentially useful in biological engineering efforts. While the two bonds are distinct, 
they overlap in many regards giving way for useful interplay. In this slightly adapted review, we 
will discuss these two bonds (H and X-bonds) and how they can substitute for one another, 
compete against each other, and be orthogonal to each other, making for a dynamic interplay. 
o 2.2 Introduction 
Hydrogen  bonds  (HBs)  are  ubiquitous  in  biology1,2 as they are the noncovalent 
interactions responsible for controlling, for example, the assembly of the DNA and RNA double-
helices 3-5 and  maintaining  higher-order protein conformations6.  Interest  in halogen bonds 
(XBs) has seen a revival in the past couple of decades, as the potential to exploit their unique 
properties has become better recognized 7-9 XBs are widely applied to the chemical engineering 
of crystals and supramolecular assemblies, 10-11 including designing liquid crystals 12-15, and  
 
1 Adapted from published article “Relationships Between Hydrogen Bonds and Halogen Bonds in Biological 
Systems.” by Rowe, R. K.; Ho, P. S (2017) 
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organometallic frameworks16,  stabilizing volatile liquids 17,  synthesizing organic catalysts 18-20 
designing anion receptors 21-28 and in host–guest assemblies 29-33. In  biology 34-35 XBs are seen to 
direct DNA macromolecular conformations36, to increase the affinity of agonists37 and 
antagonists to protein targets 35,38-42, and more recently in rational  drug design 23,41-43. 
XBs are  understood  to be analogous and comparable  to HBs in terms of their 
similarities in geometries and energetics 44; thus, it would be conceptually simple to replace an 
HB with an XB for applications in both medicinal chemistry and biomolecular engineering. In 
this review, we explore the relationship between the two molecular interactions, in terms of how 
they compete against each other, are substituted for one another, and are orthogonal and thus 
independent of each other. We focus specifically on examples in biological systems and in 
particular those relationships that are supported by structures from X-ray crystallography. First, 
however, we start  with some background on the individual ‘bonding’ interactions to provide 
the reader with some context for these relationships. 
o 2.3 A Brief History: Hydrogen Bonds and Halogen Bonds 
Linus Pauling first recognized the significance of the HB in his models  for  the  a-helix  
and  b-sheet  45-46 (Fig. 2.1), describing the interaction as ‘ . . . an atom of hydrogen is attracted  
by rather strong forces to two atoms, instead of only one, so that it may be considered to be 
acting as a bond between them’4 7 . The International  Union  of  Pure  and  Applied  Chemistry  
(IUPAC) published a more modern definition, which has its roots in the Pauling definition, but 
expands upon it to include a list of criteria by which an HB can be identified 48. The HB is now 
recognized as a weak, noncovalent interaction with some degree of directionality that falls 
between the nondirectional van der Waals interaction and the highly directional covalent 





























Structures of the a-helix and, b-sheet, with intra-strand HBs in the helix and inter-strand HBs 
in the sheet. Adapted from van Holde et al. (2006) 57. 
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acceptor (in the D—H. . .A interaction, where D is the heavy atom to which the hydrogen is 
covalently bound and A is the electron-rich acceptor atom). The resulting broad range of   
stabilization   energies   (accepted   to   be   from   2   to  272 kJ mol-1 50) has led to an artificial 
distinction between strong HBs (including the Pauling HBs N—H. . .O,   N—H. . .N,   O—H. . 
.O,   O—H. . .N   and   O— H. . .O-   interactions) and weak HBs (C—H. . .O, C—H. . .N and 
C—H. . .p). The fundamental physical roots of the interaction are recognized to be primarily 
electrostatic, with contributions from polarization and dispersion, although the role of 
covalency, as originally espoused by Pauling 47, is still debated. 
In biology, there is no doubt that the HB plays a large role in defining molecular structure 
and function 1,52. The hydrophobic effect in protein folding, for example, has been attributed to 
the loss of entropy in forming strongly hydrogen-bonded water clathrates around alkyl and 
aromatic C atoms53,54. Although the HB was key to Pauling’s models for helices in proteins 45,46, 
the connection was lost in his triple- helical model of DNA 55. The significance of HBs in 
conferring specificity in base pairing, however, was not lost on Watson & Crick 56 in their double-
helical model of DNA. The complementary nature of Watson–Crick base pairing, and its variants 
in DNA and RNA, lay the foundation  for  modern  molecular  genetics58 and the technological 
advances in genome manipulation that followed 59. 
The halogen bond traces its roots as far back, if not further, as the HB. Interactions 
between halogens and electron-rich atoms to  form Lewis acid–base complexes were known 
as early as the 1800s 60,61. The recognition  that  such  complexes are  ‘bridging’ or  ‘bonding’-
type interactions came from the crystallographic studies of Hassel & Strømme62, later called 
‘charge-transfer bonds’ 63 as an extension of Mulliken’s charge-transfer theory64,65.  
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The interaction was seen to be analogous to the HB by Bertrá n and Rodrı́guez 66, leading  to  
the  more  widely accepted term ‘halogen bond’ 67,68. 
XBs are understood to be primarily an electrostatic interaction between a halogen bond 
donor and an electron-rich acceptor atom 9,69(O, N, S; Fig. 2.2). As with the HB, however, there 
remains considerable debate  as to whether  the  XB is entirely electrostatic. High-level  
computational   studies  suggest  that   dispersion70 and steric effects may be more important   
than   electrostatics  in  conferring  directionality71. The role of charge transfer in defining the 
interaction has been resurrected72-74 , while several competing electrostatic models have also 
been put forward 75,76. 
Without delving deeply into the merits of all the competing models, perhaps the most 
accessible explanation for how halogen substituents of covalent compounds interact with 
electron-rich  acceptors  is  the  s -hole   theory  (Fig. 2.3),  as articulated by Clark, Murray & 
Politzer 77. In this model, a so-called ‘s-hole’ develops as the valence electron in the half-filled 
pz atomic orbital is pulled into a covalent  s-bond between the halogen and bonded partner. The 
depopulation of the pz orbital results in a depletion of the electron density, which accounts for 
the electropositive charge and flattening of the atomic radius diametrically opposed to the s-
bond – this is the s-hole. However, the px,y  atomic orbitals that are perpendicular to the s-
bond retain their full complement of electrons, leaving an electronegative belt around the 
halogen waist. Thus, halogen substituents are amphipathic78-79, potentially serving 
simultaneously as an XB donor in the direction of the s-hole and HB or XB acceptor in the 
perpendicular direction. 
The size of the s-hole increases with the size and polarizability of the halogen; therefore, 




Comparison of HBs to XBs. The HB donor is a hydrogen (H) attached to an electronegative atom, 
which withdraws electron density from the H, allowing  an  electron-rich  acceptor  to  interact  
electrostatically  at  a distance that is shorter than the sum of their respective van der Waals 
radii (SrvdW). In biological systems, HB donors include any H—N, H—O or H—S group on a 
protein, nucleic acid or other molecule, including the solvent. XB donors in biology include 
halogenated ligands, including inhibitors and drugs, along with oxidatively halogenated amino 
acids and nucleic acid bases. HBs and XBs share a common set of acceptors, formally neutral or 
anionic O atoms (O or O-), nitrogens, sulfurs and aromatic electron systems (p). Adapted from 










The s-hole model for XB. The valence electron from the pz-atomic orbital of a halogen, when 
paired with that of a carbon, results in a s-bond (C—X bond), which depopulates the lobe of the 
pz-orbital opposite this covalent bond. As a result, the halogen is flattened relative to its standard 
rvdW, and the charge distribution is anisotropic, with the halogen holding a partial positive charge 
(d+) opposite the s-bond (this is termed the s-hole) and partial negative charge (d-) perpendicular 
to the s-bond. Adapted from Scholfield, Ford, Vander Zanden et al. 104. 
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partner also plays a role in determining the size of the s-hole, with electron-withdrawing groups 
enhancing and electron-donating groups diminishing the electropositive crown. Taken together, 
the XB is seen to be highly ‘tunable’ 35,80-85. 
The s-hole model has been proposed as a unifying concept to explain a broad range of 
electrostatically driven interactions (including halogen, chalcogen and pnictogen bonds 87-89). 
The HB from this perspective is seen as an extreme example,  where  the  s-hole   is  manifest  
as  a  near-naked proton 90. This concept thus provides the backdrop for the similarities between 
XBs and HBs, including commonalities in geometric constraints and acceptors. 
When viewed from the perspective of the approach of the acceptor towards the donor 
(the q1 angle), both HBs and XBs are directional, with a tendency of being linear 
69 (q1= 180°). 
XBs, however, as a consequence of the anisotropic distribution  of charge, are  more strongly 
directional 67,91-93 and are  thus more  geometrically constrained than HBs. 
In this review, the relationships between  HBs  and  XBs  are explored in greater detail 
from a biomolecular perspective (Fig. 2.4). By  competing or substituting  an XB for an HB, the 
geometries and energies of the two interactions are compared and contrasted. Alternatively, the 
amphipathic nature of halogens and the commonality in acceptors  with HBs  can  result  in the  
interactions  being  orthogonal to each other from an intra and intermolecular perspective. 
o 2.4 Competitive Relationships: HB against XB 
HBs and XBs share identical sets of acceptors, which naturally leads to the two interactions 
competing against each other, with several studies taking advantage of this competitive 
relationship to compare the stabilizing potentials of the two interactions. In a small molecule 
example, Corradi et al. 94  had developed a competition assay in which a bipyridine derivative is 






Relationships between HBs and XBs in biology. (a) Competing and substitution relationships. (b) 
Two classes of orthogonal relationships. The relationship on the left takes advantage of the 
amphipathic nature of the charge distribution of the halogen, allowing it to serve as both an XB 
donor and HB acceptor. On the right, an XB and HB that share a common acceptor can be 
orthogonally related to each other. 
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win out. In a similar study, Aakeröy et al. 95 showed that  the  two interactions competed in the 
co-crystallization of 4,4’ -azabi- pyridines, with XBs showing distinct differences in donor type 
(Br versus I), while the various HB donors behaved very similarly to each other. 
The only truly analogous crystallographic study that competes an XB directly against an 
HB in a biological system centers around  a model DNA assembly called the Holliday junction, 
in which XBs have been engineered to ‘direct’ the conformation of the junction 36, 96  (Fig. 2.5). 
The structure of the Holliday junction in an inverted repeat decanucleotide sequence had been 
shown to be stabilized by a set of HBs from the cytosine base of a C•G base pair to the phosphate 
oxygen at the positions where the DNA strands kink and thus cross over to link two near- 
continuous double-helices 97-100. In this system, one set of C•G base pairs was replaced by a 
BrU•A  base pair (where BrU  is a 5-bromouracil), with the corresponding HB replaced  by an 
XB 36. In order  to determine whether the XB or HB was the stronger interaction, two 
complementary strands of DNA (one with the native C•G base pair, and one with the halogenated 
xU•A base pair) were designed to assemble into a four-stranded complex. If the HB is favored 
over the XB, then the C•G base pair would be seen at the cross-over strand of the resulting 
junction, and vice versa. By determining the ratio of Br at the crossing and non- crossing strands 
in the single-crystal structure, the Br XB energy was estimated  to be ~17 kJ mol-1   more 
stabilizing than the competing HB in this DNA system.  
The work of Carter et al. 96  extended this crystallographic assay to F, Cl and I, and applied 
differential scanning calorimetry (DSC) to determine the explicit stabilizing potentials in 
solution101.  From the crystallographic studies, the ability of XBs to effectively compete against 




Competing HBs and XBs in a four-stranded DNA Holliday junction. A DNA assembly is 
constructed in which one set of strands (cyan) has cytosines that can form HBs to the DNA 
backbone to stabilize the junction, paired with a complementary set of strands (red) that places 
halogenated uracils at the analogous positions that can form XBs to the backbone. The HB 
stabilized junction is in the H-isomer, which must compete against the XB-stabilized X-isomer, 
with the isomer that is seen to be dependent on whether the HB or XB is more stabilizing. Adapted 
from Voth, Hays & Ho 36 , PDB code 2org. 
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In addition, the  geometries of interaction  become more ideal (shorter interaction 
distances and more linear q1 angles of approach) as the XB becomes more favorable. The series 
was recapitulated in DHM from DSC studies, becoming more positive moving from F to I 96. 
However,  an  enthalpy–entropy  compensation  effect was observed, where the very strong 
enthalpic iodine XB was also associated with a loss in dynamics of the system and a concomitant 
loss in DG of stabilization. Consequently, the Br XB was seen to be the most stable interaction 
overall in the DNA junction system, leading to the obvious conclusion that an enthalpically stable 
interaction may come at an entropic cost. Thus, when trying to apply XB concepts to molecular 
engineering, particularly in biological systems, it is important to consider not only the obvious 
enthalpic effects, but also how introducing such a stabilizing interaction affects the dynamics of 
the molecular system (including the solvent). 
o 2.5 Substitutions: XB for HB 
While the competition assay in the DNA Holliday junction is fairly straightforward and 
easily interpretable, developing an analogous direct competition between an HB and XB proves 
to be much more difficult in a protein system. An alternative approach is to determine how 
replacing an HB donor with a halogen affects structure and function in a protein. In one such 
study, Kraut et al. 102  asked how replacing the HB with an XB would affect the catalytic function 
of ketosteroid isomerase (Fig. 2.6). In this enzyme, replacing a Tyr residue (Y16), which forms 
an HB to the oxyanion hole in the active site, with a non-interacting Phe dramatically reduces 
the catalytic activity. The expectation was that replacing this Tyr with para-halogenated  Phe (F, 
Cl or Br) would introduce an XB  that  could  restore  or  possibly  enhance  the  catalytic 
activity. None of the halogenated constructs, however, had kcat or kcat/KM values that were 
comparable to the wild-type. Unfortunately, since the halogenated substrates were models rather  
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than crystal  
 
Figure 2.6 
Structure of ketosteroid isomerase bound to the estrogenic steroid hormone equilenin (a). (b) Detail 
of the interactions from Y16 and D103 to the oxyanion hole (O-)  of equilenin. (c) Model of the 
construct in which Y16 is replaced by a chlorinated Phe residue (ClF). The distance from the 
chlorine to the oxyanion hole was estimated to be ~72% of the SrvdW, suggesting the formation 
of an XB. Data from Kraut et al. 102, PDB code 5g2g.  
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structures, it is difficult to assess whether  any XB was actually formed, leaving the  question 
open as to how comparable an XB is to an HB in this enzyme system. 
 Our laboratory has started to construct a system to directly determine the effect that 
replacing an HB with an XB has on protein stability by introducing unnatural halogenated amino 
acids103 site specifically into  T4 lysozyme 104 (Fig. 2.7a), a classic model for studying effects of 
non-covalent interactions on protein stability 105. As  with the  isomerase  studies, we have 
replaced a tyrosine with para-halogenated phenylalanines, but we have studied  the  effects  of  
the  HB  to  XB  substitution  on  the structure by X-ray crystallography, and on its thermodynamic 
stability. In this case, the crystal structures demonstrated that the Br and I constructs formed XBs 
(Figs. 7b and c). Although these constructs were overall less stable than the wild-type, it was clear 
that the XB helped to partially rescue the general destabilizing effect that halogenation has on 
protein stability at a control site that could not form an XB.  
Short  of  substitutions  within  an  intramolecular  system, examples from ligand 
binding35, 38, 40, 42, 106-109 provide insight into how replacing an HB with an XB affects stability, 
not in a protein per se, but in a protein– ligand complex. The caveat, of course, is that it is 
difficult to decipher contributions from single isolated interactions to the overall binding affinity 
110. Well-designed studies, however, could allow a semiqualitative assessment of the stabilizing 
potential between HBs and XBs. For example, there have been extensive studies on protein 
kinase inhibitors as potential anticancer drugs, with many inhibitors being ATP analogs that are 
halogenated and involve XBs for recognition and specificity106. An interesting study from 
Johnson’s group 111 showed that XBs substituting for HBs from ATP define the specificity of 
the inhibitor 5,6-dichlorobenzimidazone-1-,b-d-ribofuranoside (DRB) for Cdk9 over the 





XBs engineered into T4 lysozyme. (a) Two aromatic sites (Y18 and Y88) where standard Tyr 
residues were replaced by bromophenylalanine (brF), (b) or iodophenylalanine (iF), (c). (b) The 
brF construct at Y18 shows the bromine pulled towards the peptide oxygen to within 100% of the 
SrvdW. (c) The iF engineered protein at Y18 shows the iodine pulled even closer (93% of SrvdW) 
to the oxygen to form a stronger XB. Substitutions at Y88 show no distortions to the protein 
structure, and are highly destabilizing. Adapted from Scholfield et al. 104. 
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Cdk9 is the kinase subunit of the transcription  elongation  factor b, while Cdk2 promotes the 
formation of the nuclear pore complex during cell division; thus, the specificity of DRB is 
important in defining which cellular pathway and the type of cancer the inhibitor will target. 
The crystal structure  of the Cdk9-inhibitor complex showed that the purine ring of DRB is in 
the anti-conformation, allowing two XBs from the chlorines to substitute for the two HBs that 
would normally form with the ATP substrate 112  in the binding pocket (Fig. 2.8). In contrast, 
DRB in the ATP pocket of Cdk2 has a predominant  form in which the chlorinated purine ring 
is in the syn-conformation, which allows for the formation of only a single Cl XB. This difference 
in binding modes accounts for the  near  300-fold difference in IC50   values of the  inhibitor 
against CDK9 versus CDK2. 
Fanfrlı́k   et  al. 113  took  the  opposite  approach by substituting an amine (NH2, an HB 
donor) for the XB donor (Br or I) found in an inhibitor against aldose reductase (Fig. 2.9). The 
crystal structure of this non-halogenated  inhibitor in the ligand binding site of the enzyme 
showed that indeed an HB was formed, as proven by the short donor-to-acceptor distance. A 
comparison of combined quantum mechanical/ scaled QM/molecular mechanical (QM/SQM/MM) 
calculations (in the gas phase) on the amine to the two XB inhibitor– enzyme complexes showed 
that the HB inhibitor had the most negative energy of interaction. However, the amine inhibitor 
pays a hefty desolvation penalty compared with the halogenated inhibitors, resulting in an 
overall score and free energy that is least favorable in this comparison. These trends were borne 
out experimentally, with the iodinated inhibitor having the lowest IC50 value. Thus, we must take 
into account the solvent effects when trying to design inhibitors against their protein targets 114. 
 Collectively, these studies show that we cannot simply substitute a halogen for an HB 




The inhibitor complex of Cdk9 or Cdk2. (a) The structure of Cdk9 (traced in cyan, PDB 3my1) 
with the DRB is overlaid on that of Ckd2 (traced in purple, DPB 3my5) with DRB in their 
respective ATP binding sites 111. (b) Structural details of Cdk9 bound to ATP (in the anti-
conformation) show hydrogen bonds (blue dots) between the adenine base and the protein 
backbone in the hinge region of the kinase 112 (PDB code 3blq). (c) Chlorines (green spheres) of 
the DRB inhibitor (in the anti-conformation) form two XBs (magenta dots) and an HB to the 
peptide backbone of Cdk9. (d) The major conformation of the DRB inhibitor is rotated to the syn-
conformation, allowing XBs (magenta dots) only to form one XB to the peptide bond, and an XB 





Crystal and modeled QM/SQM/MM structures of aldose reductase in complexes with the inhibitor 
{2-[(4-amino-2 fluorobenzyl)carbamoyl]-5-chlorophenoxy}acetic acid. The inset shows the 
crystal structures of the inhibitor, with the substituent X = Br (yellow), I (orange) or NH2 (blue). 
The QM/SQM/MM modeled structure aligned well with the respective crystal structures, and both 
indicate that replacing the halogen with NH2 did not alter the binding mode. Adapted from Fanfrlı́k 
et al. 113, PDB code 4qxi.  
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As with the competition assays, any efforts to rationally engineer such substitutions 
must be aware of the more restrictive geometry constraints for the XB and, therefore, be ready 
to accept that what appears  initially to be a logical replacement  may end with less than 
satisfying results. When trying to substitute an HB with a halogen on a ligand such as an 
inhibitor, we must also take into account solvation effects on the unbound and bound  molecules 
– recognizing that halogens are  generally hydrophobic atoms 115. 
o 2.6 Orthogonal Relationships: XBs perpendicular to HBs 
Orthogonality as a concept extends to both geometric as well as functional properties 
when considering HBs and XBs. We will see that the geometric definition – that the interactions 
can be perpendicular to each other – will be evident from two properties of halogens: (i) the 
amphipathic nature of the halogen and (ii) the ability to share a common electronegative acceptor 
with an HB donor. 
Recall that the charge across the surface of a halogen substituent is anisotropically  
distributed 35 , with a partial positive charge opposite and an electro- negative belt perpendicular  
to the covalent s -bond  (Fig. 2.3), allowing it to act as both an XB donor and an HB acceptor 
(Fig. 2 .4). This charge distribution allows for the halogen to partake in two simultaneous 
interactions. We have seen intermolecular X-bonds through the s-hole and intermolecular H-
bonds to the negative belt. More recently though, we have seen intramolecular H-bonds. That is, 
an H-bond donor on the same molecule forming an H-Bond to the halogen and increasing the size 
of the s-hole on the halogen through polarization116,117. This unique interaction we note to be a 
Hydrogen Enhanced Halogen bond (HBeXB Bond), and will be reviewed in more detail in Chapter 
3.   
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Lu, Wang et al. 118 surveyed the  Protein  Data Bank (PDB 119) and found that  the most 
frequent HBs to halogens (X = Cl, Br or I) in crystal structures of protein–inhibitor complexes 
were from C—H donors, followed by N—H, then O—H. As expected, the most probable HB 
approach to the halogen was  ~100o (close to the 90o predicted from charge distributions) and 
the H. . .X distances shortened  when going from weaker to stronger HB donors (C—H. . .X > 
N—H. . .X > O—H. . .X in terms of the H. . .X distance). The trends in the interaction distances, 
as reflected in the HB energies, were consistent with quantum chemical calculations (at the 
MP2 level) on model HB complexes between halogenated benzene and CH4, NH3  or H2O 
donors.  
Lu, Wang et al. 118 found only three PDB entries (one crystal structure and two NMR 
models) with a halogen serving as both HB acceptor and XB donor. The one crystal structure 
(PDB 1gjd) was of a trypsin-like serine protease in a complex with an iodinated analog of APC-
8696, an amidine inhibitor 120. The authors  had shown that replacing a single hydrogen with a 
halogen increased the  specificity of APC-8696 by up to 220-fold for the class of proteases with 
a Ser at position 190 (which includes the urokinase-type plasminogen activator and factor VIIa) 
over a similar class of inhibitors with an alanine in place of Ser190. The structure with the 
iodo-analog shows an XB to the carbonyl oxygen of Val41 (Fig. 2.10), but also two sets of C—
H. . .I HBs (from the Ca of G193 and Cb of S195) orthogonal to the XB 118 . In addition, the amino 
NH of G193 and the OH of Ser195 are also within HB distance to the iodine, thus potentially 
expanding the sphere of interactions that are orthogonal to the XB. 
The ability of an electron-rich atom to serve as an acceptor for both HBs and XBs sets up 
a different class of orthogonal relationship, in which simultaneous bonds to a common acceptor 





Structure of the iodinated APC-8696 inhibitor in complexes with trypsin, a Ser190 trypsin-like 
serine protease120. The inset shows the iodine of the inhibitor forming an XB (magenta dashes) to 
the backbone oxygen of Val41, along with two HBs (blue dashes) from Gly193 and Ser195 that 
were identified by Lu, Wang et al. 118. In addition, the iodine is within HB distance of the backbone 
amino group of Gly193 and the hydroxyl group of Ser195 (cyan dashes).  
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evidence for this relationship came initially from a survey of the PDB by Voth et al. 121, which 
showed that an XB from a halogen to an acceptor (typically the halogen of an inhibitor to the 
carbonyl oxygen of the polypeptide backbone) is geometrically perpendicular to and HB that 
shares this same acceptor (with an average —X. . .O. . .H— angle of  ~88o ; Fig. 2 .11a). An analysis 
of the secondary structures (a-helices and b-sheet conformations) shows that this geometric 
orthogonality is inherent in the relationship between the two bond types. The HBs between 
strands in a b-sheet are approximately aligned along the peptide planes, placing the shared XB 
perpendicular to the plane and the b-strands. In contrast, the HBs within an a-helix are  aligned  
~40o  out of the  peptide  plane. Consequently, XBs approach the peptide planes in an a-helix 
at an angle  of  ~50o   to  maintain  the  orthogonal  geometry.  In addition to their geometric 
relationship, the two interactions were shown to  be energetically orthogonal.  Quantum chemical 
calculations on a set of model compounds that mimic interactions from halogenated  ligands to 
the hydrogen-bonded peptide backbone indicated that adding or removing an XB to the carbonyl 
oxygen acceptor does not affect the energy of the HB peptides (Figs. 11b and c). Thus, by analyzing 
the HB pattern in a ligand binding site of a protein, we can predict the optimum geometry of a 
stabilizing XB and that adding the XB will not  significantly disrupt  the  structural  integrity  of 
the folded protein. 
Vasylyeva et al. 122 applied  the  orthogonality  concept  to drive the self-assembly of N-
methylacetamide (NMA, a peptide backbone mimic) with a series of halogenated  aromatic 
compounds (as XB donors), with the goal of developing the concept for future crystal 
engineering projects. In such cocrystals, the NMA molecules packed in a way that mimicked the 
polypeptide backbone in b-sheets, with HB donor/acceptor pairs aligned in the peptide plane. 




Orthogonal HBs and XBs that share a common acceptor. (a) Distribution of X---O-H angles seen 
in the PDB (Cl in green bars, Br in red bars and I in purple bars). (b) Energy of HB peptide bonds 
(EHB) in the presence (magenta squares) or absence (black squares) of an orthogonal XB. (c) 
Energy of an XB (EXB) in the presence (blue circles) or absence (black circles) of an orthogonal 
HB. Adapted from Voth et al. 121. 
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sheets, with their halogens halogen-bonding to the carbonyl O atoms. As expected, the —X. . 
.O…  H— angles varied between 77.9 and 98.5o , in agreement with Voth et al. 121. 
The orthogonality concept has now been seen to extend to assemblies of non-
protein/peptide  molecules as well. Takemura et al. 123 observed orthogonal XBs and HBs in 
co- crystals of  1,4-diiodotetrafluorobenzene  with acetamide  or with N-methylbenzamide. In 
these crystals, the respective amides form HB sheets, with the opposing iodines of each 1,4- 
diiodotetrafluorobenzene forming XBs that bridge the carbonyl O atoms across two neighboring 
amide sheets. The average   —X. . .O. . .H—  angle   in   each   case  (~80o )   is geometrically 
orthogonal. 
While much has been carried out on the halogen atom acting as a site for two 
intermolecular interactions, our lab and the Berryman lab simultaneously uncovered the 
ability for an intramolecular H-bond to form to the halogen. As the H-bond forms to the 
negative belt around the halogen, an increase in the s-hole size is noted (Fig. 2.12). This 
enhancement is thought to come from the polarization of the electron density by the H-
bond toward the pXY oribitals. We term this variation of an orthogonal X-bond the 
Hydrogen Enhanced Halogen bond (HBeXB bond). In engineering meta-halogenated 
tyrosine into T4 lysozyme, Carlsson et al 117 found through DSC, crystallography, and 
quantum mechanical calculations that the hydroxyl group on the tyrosine (when oriented 
toward the halogen), could increase the thermal stability, enthalpy, and activity of the 
enzyme. Due to the pre-existing structural rigidity of the protein, only meta-chloro-
tyrosine formed a stabilizing HBeXB bond. Riel et al. 116  was working on an organic small 
molecule example of this at the same time. They were able to increase the size of the s-
hole of two iodines on a planar aromatic compound with the presence of an NH2 group.  
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Figure 2.12  
Electrostatic potential maps of 2-chlorophenol, 2-bromophenol, and 2-iodophenol showing how 
the size of the s-hole increase as the hydrogen rotates from the trans non-HB orientation to the 
cis HB orientation. ESP of halobenzene molecules are to the right for s-hole size comparison. 
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This bidentate compound was able to bind halides at a much higher affinity compared to a 
similarly designed compound with hydrogens instead of iodines. Herein is another example 
of a H for X substation that increases binding affinity, while also demonstrating the utility 
and power of the HBeXB bond that has only recently been identified.  
The X—H orthogonality concept is now finding utility in the design of inhibitors against 
therapeutic  targets. In one interesting example, Huang et al. 124 designed a peptide inhibitor 
against the oncoprotein encoded by the mouse double minute-2 (MDM2) gene (Fig. 2.13), a 
ubiquitin ligase E3 specific for p53 tumor suppressor protein. The authors based their design on 
a 12-amino acid peptide from p53, which included metabromophenylalanine   at  the  third 
residue.  Quantum chemical and QM/MM hybrid calculations suggested that the halogenated  
residue forms an XB to the peptide oxygen of Gly58 of the MDM2 protein, which is further 
perpendicular to an HB from the amino group of the Met62 peptide bond. The orthogonal 
interaction was estimated to increase the affinity of the halogenated  ligand by fourfold. Thus, 
the orthogonal XB/HB serves as a starting point in designing new halogenated inhibitors 
against clinically important  targets 109. 
o 2.7 Perspectives 
The HB is ubiquitous in biology1,2, responsible for defining the conformational details 
of proteins and nucleic acids, the interactions that determine the specificity between the two, and 
the affinity of various ligands for each. With the growing recognition that XBs are important in 
biology 34, 35, 108 particularly in agonists and antagonists that bind clinically important targets, the 
relationships between the two interactions are seen to be strongly related to each other, often 
times in relationships that are more complex than the simple competition that we would expect 




MDM2 in complexes with a peptide derived from the p53 tumor suppressor. AC—H ----O HB is 
seen from the aromatic side chain of F3 to the peptide oxygen of G57. An orthogonal HB to this 
same oxygen originates from the peptide amide of M61. When the hydrogen at position 3 of F3 
is replaced by a halogen (H/X), an energetically independent orthogonal molecular interaction 
could form to help stabilize the peptide–MDM2 complex. Adapted from Huang et al. 124 , PDB 
code 3jzo.  
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compete against, or be orthogonal to HBs. However, these interactions and their respective 
contributions to molecular structure have primarily been seen in hindsight. In order to take 
advantage of these relationships in medicinal chemistry or biomolecular engineering, the 
individual interactions and their more complex relationships need to be more accurately modeled 
and thus be rationally designed. Quantum mechanical (QM) calculations can now accurately 
model complex interactions, including XBs and HBs; however, most biological systems remain 
recalcitrant to high-level QM methods109. Molecular mechanics approaches to modeling the XB 
are being developed and refined 86, 125-130, but the remaining challenge is in how to treat the 
competitive and orthogonal relationships. 
Throughout this review, water is seen to play an important role in affecting relationships 
between HBs and XBs. In addition to their electrostatic interactions, halogens are known to be 
hydrophobic. Introducing halogens, either in replacement of or in addition to OH or NH 
groups, will therefore change the solvation pattern around a protein or nucleic acid structure, 
and these must be taken into account when trying to understand the energetics of XBs in biology. 
Furthermore,  it has been shown that  waters can mediate between halogens and both HB donor 
and acceptor groups in protein–ligand complexes 131. 
As the molecular interactions seen in crystal structures of proteins and nucleic acids 
become better studied and methods to identify   such   interactions   become   better   developed 
132-136 we will invariably find additional, perhaps  more complex relationships that may not fit 
neatly into any of the ones discussed here. The substitution of a hydroxyl or amine group with 
a halogen replaces not only an HB donor with an XB donor, but the HB acceptor functions are 
also affected. Although a halogen can also serve an HB acceptor, the angle of approach of the 
donor differs among each of these substituents. XBs were found to be important in biology 
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not from any preconception that they should be, but from finding that what was already present 
in the PDB 119 could not be explained from a biologist’s simple understanding of halogens and 
their chemical properties. In short, there remains much to be learned about molecular interactions 
from single-crystal structures, not only about how proteins and nucleic acids function in the cell, 
but also about fundamental chemical properties that may be surprising not only to the biologist, 
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CHAPTER 3: HYDROGEN BOND ENHANCED HALOGEN BOND: A SYNGISTIC 
INTERACTION IN CHEMISTRY AND BIOCHEMISTRY1 
 
 
o 3.1 Summary 
The halogen bond (XB) has become an important tool for molecular design in all areas of 
chemistry, including crystal and materials engineering and medicinal chemistry. Its similarity to 
the hydrogen bond (HB) makes the relationship between these interactions complex, at times 
competing against and other times orthogonal to each other. Recently, our two laboratories have 
independently reported and characterized a synergistic relationship, in which the XB is enhanced 
through direct intramolecular HBing to the electron-rich belt of the halogen.  
In one study, intramolecular HBing from an amine polarizes the iodopyridinium XB donors 
of a bidentate anion receptor. The resulting hydrogen bond enhanced halogen bond (or HBeXB) 
preorganizes and further augments the XB donors. Consequently, the affinity of the receptor for 
halogen anions was significantly increased. In a parallel study, a meta-chlorotyrosine was 
engineered into T4 lysozyme, resulting in a HBeXB that increased the thermal stability and activity 
of the enzyme at elevated temperatures. The crystal structure showed that the chlorine of the 
noncanonical amino acid formed an XB to the protein backbone, which augmented the HB of the 
wild-type enzyme.  
In sum, the two systems described here show that the HBeXB concept extends the range 
of interaction energies and geometries to be significantly greater than that of the XB alone. 
 
1 Adapted from published article “Hydrogen Bond Enhanced Halogen Bonds: A Synergistic Interaction in 
Chemistry and Biochemistry” by Asia Marie S. Riel, Rhianon K. Rowe, Ethan N. Ho, Anna-Carin C. Carlsson, 
Anthony K. Rappe, Orion B. Berryman, and Pui Shing Ho (2019)  
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Additionally, surveys of structural databases indicate that the components for this interaction are 
already present in many existing molecular systems. The confluence of the independent studies 
from our two laboratories demonstrates the reach of the HBeXB across both chemistry and 
biochemistry and that intentional engineering of this enhanced interaction will extend the 
applications of XBs beyond these two initial examples. 
o 3.2 Introduction 
The hydrogen bond (HB) has become a central topic in chemistry, since it was first 
described in water nearly a century ago1-4. In structural biochemistry, HBs are the primary 
noncovalent interactions that define the functional conformations of nucleic acids and proteins5-7.  
More recently, the halogen bond (XB)8  and its cousins (e.g., the chalcogen, pnictogen, and tetrel 
bonds) are becoming increasingly recognized as important contributors to molecular assembly and 
recognition across diverse fields of chemistry, chemical engineering, and biology9. The 
relationships among these various noncovalent interactions can be complex, particularly when two 
or more are present in the same system10-12.  Here, we highlight a synergistic relationship, recently 
described separately in a chemical and a biochemical system, in which a HB greatly enhances the 
XB potential of a halogen substituent. The principle behind this HB enhanced XB (HBeXB for 
short) can potentially be applied to other pairs of noncovalent interactions, thereby extending their 
range of energies and, consequently, applications as design tools for molecular engineering. 
o 3.3 Experimental Characterization of the HBeXB 
 We present here rare quantification of intramolecular HBeXBing in solution with 
supporting computational and crystallographic evidence, in which a HB to a halogen substituent 
increases the XB donating potential. This HBeXB was quantified in a bidentate halide receptor 19  
and, independently, with a meta-halotyrosine-modified enzyme 20. The manifestation of HBeXBs 
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in both small molecules and a protein suggests that this synergistic interaction will be widely 
relevant across the fields of chemistry. In this Account, we summarize the studies characterizing 
the HBeXBs in these two experimental systems. In addition, we present results from surveys of 
structural databases indicating that HBeXBs are highly prevalent across a broad range of chemical 
compounds and complexes. 
o 3.3.1 HBeXB Increases Anion Binding 
 The Berryman laboratory recently developed bisethynylpyridinium XBing receptors that 
bind anions and neutral Lewis bases in a bidentate fashion 21,22.  The alkynes promote rigidity and 
directionality; however, their low rotational barrier allowed the scaffolds to adopt three planar 
binding conformations. After considering ways to preorganize the structure, we determined that 
macrocyclization and external intramolecular HBs (away from the binding site) were not 
synthetically tractable. Instead, we introduced an electron-deficient aniline to HB to the electron-
rich belt of the XB donors. This internal intramolecular HB was a unique departure from traditional 
preorganization techniques in that it also directly enhances XB donor strength. 
First generation 1,3-bisethynyl iodopyridinium 1  (no intramolecular HB donor) and 
second generation 2  (intramolecular HB and fluorine) receptors were recently synthesized (Figure 
3.1). The HB’s role in preorganization and enhanced XBing (in 2) as compared to our first-
generation receptor (1) was quantified by 1HNMR titrations with chloride, bromide, and iodide. 
Intramolecular HBeXBing increased halide binding by nearly 9-fold over 1  (in 40% CDCl3 /60% 
CD3NO2 ), which lacked the HBeXB. The halide K11  values for 2  are 23 700 M−1  for Cl− , 32 
900 M−1  for Br− , and 36 900 M−1  for I− . However, 1  binds halides much more weakly, with 
association constants of 2630 M−1  for Cl− , 4690 M−1  for Br− , and 4380 M−1  for I− . The 











Schematics of first generation XB receptor (1 and 1Me) and second generation XB and HB 
receptors (2, 2Me, and 3). Syntheses can be found in the original publications 20,21. Adapted with 
permission from Riel et al.19  Copyright 2018 Royal Society of Chemistry.  
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ion pairing to balance charge. To further assess the HBeXB and verify that the amine is not the 
primary contributor to the increased binding strength, we compared 2 to 3 , which lacks the XB 
donors. We observed nearly an order of magnitude stronger binding for 2  compared to 3, 
concluding that the amine HB donor of 3  does not significantly contribute to the anion affinity in 
this system. These first solution studies of HBeXBing demonstrate that intramolecular 
preorganization and enhanced XBing is operable and contributes to the improved halide 
recognition. 
 Simultaneous preorganization and enhancement of the XB was further confirmed by gas-
phase computations (B3LYP, 6-31+G(d,p), aug-cc-pVTZ and LANDL2DZdp ECP). DFT single 
point energy calculations demonstrate that the bidentate conformation, with intramolecular HBs, 
is more stable than the conformation without HBs by 1.29 kcal/mol. Additionally, electrostatic 
potential (ESP) maps illustrate that 2Me , with the intramolecular HBeHBs, contains a larger more 
electrophilic σ-hole (Figure 3.2b) compared to 1Me, which lacks the HBeXBs (Figure 3.2a). 
Additional ESP maps of 2Me  with no amine (Figure 3.2c) and 2Me  with no fluorine (Figure 
3.2d) verify that the enhanced polarization is caused by the intramolecular HBs from the amine. 
The magnitude by which HBing enhances bidentate XBing was calculated through interaction 
energies of 2Me and 2Me-no NH2  (with no amine therefore no intramolecular HBs) with Br− . 
These energies with bromide highlight that the bidentate intramolecular HBeXBs in 2Me  are over 
3.2 kcal/mol stronger than solely the XBs in 2Me-no NH2, which lacks the HBeXBs. These 
calculations suggest that a single HBeXB interaction in this system provides approximately 1.6 
kcal/mol of stabilization. Together, these calculations corroborate the solution data and dual role 
of the intramolecular HBeXB to enhance the σ -hole and promote preorganization.  







Figure 3.2  
Schematics and associated electrostatic potential (ESP) maps of 1Me (a), 2Me (b), 2Me-no amine 
(c), and 2Me-no fluorine (d) showing HBeXB enhancement of the electropositive σ-holes. ESP 
maps drawn at a 0.004 au isodensity. Adapted with permission from Riel et al.19 Copyright 2018 
Royal Society of Chemistry.  
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Crystallographic data with halide counteranions provided detailed structural evidence of 
HBeXBing (Figure 3.3). When the intramolecular HB is present, we observed a 5% contraction of 
the XB distances between methyl derivatives of 2 (2Me) and both Br−  and I−  compared to 1Me. 
Additionally, the intramolecular HBeXB preorganizes the complexes of 2  and 2Me  with Br−  and 
I− , which promotes planarity in the receptor backbone. The pyridinium rings of 1Me  twist out of 
planarity up to 15° ; however the addition of the HBing amine decreases ring twist by over half, 
with the smallest angle at 2.4° . The crystals of 2  and 2Me  confirm that the intramolecular HBeXB 
can preorganize a receptor while simultaneously improving XB strength. 
o 3.3.2 HBeXB Increases Enzyme Stability and Function 
 The growth in the development of polypeptide-based therapeutics spurred the Ho 
laboratory to determine whether XBs can be engineered to stabilize protein structures, using the 
enzyme T4 lysozyme (T4L) as the model system (Figure 3.4)15. Within the active site of T4L, 
tyrosine residue (Y18) forms a water-mediated HB to the carbonyl oxygen of a neighboring 
glutamate (E11) that is essential for the enzyme’s structure and function. In order to determine 
whether an XB can replace this critical HB, we made T4L constructs in which Y18 was replaced 
by a halogenated phenylalanine (XF18, where X = Cl or I) 15.  As a control, we made analogous XF 
replacements at position Y88, a solvent-exposed residue that cannot form XBs, and found these 
constructs to be destabilizing to the protein. The XF18-T4L constructs, however, formed XBs that 
replaced the essential HB of Y18, thus rescuing the stability of the protein (with Cl < Br < I) 
relative to the Y88 controls. The rescue, however, was incomplete, in that the engineered XB could 
not entirely compensate for the loss of stability and function afforded by the essential HB from the 










Figure 3.3  
Crystal structures of 1Me with bromide top view (a, top) and planar view (a, bottom) comparing 
distances with 2Me and bromide (b). The planar views include the degrees that the pyridinium 
rings twist out of coplanarity with the benzene (a, bottom) or fluoroaniline (b, bottom) core. 






Figure 3.4  
T4 lysozyme (T4L) model system for XB studies. (a) The hydroxyl of the tyrosine amino acid at 
position 18 (Y18) forms a HB to the polypeptide backbone of glutamate E11 (dashes). The side 
chain of tyrosine at Y88, however, is solvent exposed and does not interact with the remainder of 
the protein. (b) Replacing Y18 with a meta-chlorotyrosine (ClY18) maintains the essential HB to 
E11, with the addition of a XB from the Cl to the peptide oxygen of glycine G28 (with a Cl···O 
distance of 3.11 Å or 95% of the van der Waals radii). (c) Electrostatic potentials of a chlorophenol 
model of the ClY18 side chain. The Cl substituent shows a weak σ-hole when the hydrogen of the 
OH is rotated away from the halogen (top) but becomes significantly enhanced when rotated to 
form a HB.  
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We next attempted to augment, rather than replace, the critical hydroxyl HB of Y18 by 
introducing a halogen that can form a XB to a different, nearby carbonyl oxygen acceptor (at 
G28)20.  This T4L variant was constructed by replacing Y18 with a meta-halotyrosine (XY18). The 
engineered ClY18-T4L indeed showed that the chlorine formed a XB to the peptide G28 backbone, 
resulting in a protein that was more thermally stable than the wild-type one. The melting 
temperature (Tm) and melting enthalpy (ΔHm) were both elevated (1 ° C and ∼3 kcal/mol,   
respectively), as determined by differential scanning calorimetry (DSC). In addition, this 
chlorinated construct showed 15% greater enzymatic activity over the wild-type one at 40 ° C. 
The surprising aspect of these results was that the increased stabilization and elevated 
activity came from adding a single chlorinated substituent, while the brominated and iodinated 
variants (both expected to have larger σ -holes and therefore stronger XBs) had no effect or were 
destabilizing. The iodine of the IY18 was too large to fit into the tight and rigid loop into which 
the halogen must sit and, thus, was seen to be rotated to expose the halogen to solvent, thereby 
destabilizing the protein. The BrY18 placed the intermediate sized halogen partially exposed and 
partially XBed within the protein loop (with a very short Br··· O distance of 2.88 Å or 85% of the 
van der Waals radii), with the stabilizing and destabilizing effects essentially neutralizing each 
other. Only the small chlorine fits into this loop to form a stabilizing XB, with Cl··· O distance at 
95% of the van der Waals radii, near the statistical mode for biological XBs 13. 
  The question, however, is why the Cl-XB of the ClY18 construct has such a significant 
stabilizing influence on this protein. We had previously shown that a Cl-XB to a very strong 
anionic oxygen acceptor only provides 0 to 0.5 kcal/mol of stabilizing potential in a DNA system, 
while Br- and I-XBs contributed 2 to >6 kcal/mol of enthalpic stability 14,16. Furthermore, quantum 
mechanical (QM) calculations suggest that a hydroxyl group should be electron donating to ortho 
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substituents (inset Figure 3.5) and, therefore, the chlorine of the ClY18 should be a weaker XB 
donor even compared to a ClF. 
The solution to this conundrum came from considering not simply the standard substituent 
effects of the hydroxyl group but also its ability to serve as a HB acceptor to the OH of the Y18 
side chain. QM analyses on chlorophenol models indicate that when the OH is rotated to form an 
intramolecular HB to the electronegative annulus of the chlorine, the σ -hole becomes enhanced, 
resulting in a XB-donor that is comparable to that of bromo- or iodobenzene in stabilizing 
potential. The significantly stronger XB interaction observed in ClY18-T4L can thus be attributed 
to this HBeXB. Such an intramolecular O−H··· X HB is supported by calculations and experiments 
on halophenols in nonaqueous environments 23.  In addition to its enhanced stabilizing potential, 
the QM calculations also indicate that the σ-hole encompasses a larger area of the atomic surface 
and, therefore, the HBeXB also should show a broader range of angles (θ1) for the approach of 
acceptors to the halogen XB donor 20.  The resulting enhanced XB in the ClY18 T4 lysozyme is 
thus the first recognition that a HBeXB can increase the stability and function of a biomolecule. 
o 3.3.3 Survey of HBeXB in Cambridge Structure Database and Protein Data Bank 
 Interest in the XB has dramatically increased since the turn of the century, with the number 
of annual publications on the topic growing from <10 prior to 2000 to >450 in 2017. This dramatic 
increase parallels the application of XBs as a molecular design element in nearly all fields of 
chemistry. The XB is very similar to the HB in terms of competing acceptors and interaction 
energies, but the more directional nature of the XB has been seen as a limitation, particularly in 
biomolecular engineering. However, the HBeXB has the potential to extend the application of XBs 





Figure 3.5  
Quantum mechanics (MP2) calculated energies (EMP2) of XBs from chlorobenzene to the 
carbonyl oxygen of N-methylacetamide (NMA, a model for a peptide bond) and effects from 
adjacent hydroxyl groups. The Cl-XB is fairly weak, and addition of a hydroxyl to an adjacent 
(ortho) carbon weakens the interaction further. Rotation of the OH to form a HB to the Cl, 
however, significantly increases the stabilizing potential of the Cl-XB (with EMP2 becoming more 
negative by ∼1.5 kcal/mol). The inset shows the MP2 calculated inductive effects of a hydroxyl 
(OH) substituent on charges at the carbons of benzene (phenol). The carbons of benzene carry a 
charge of −0.15e, determined through an MP2 calculation. The charges at the ortho- and para-
carbons of the phenols become more negative, reflecting the electron donating effect, while that 
of the meta-carbon become more positive, indicative of the electron withdrawing effect of the 
hydroxyl group to these positions. The Hammett constants24 for hydroxyl substituents are −0.37 
for the para- and +0.12 for the meta-position, consistent with the quantum calculated effects on 
the carbon charges. 
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expanding the atomic surface encompassed by the electropositive σ -hole and, consequently, 
extending the angles of approach by the acceptor.  
The experimental observations of HBeXBs in a small molecule anion receptor and in an 
engineered protein, involving various XB donors and HB donors, suggest that this interaction is 
applicable across a wide range of chemical systems. We thus addressed the question of whether 
HBeXBs could be present in other chemical systems by surveying the Cambridge Structural 
Database (CSD25) for structures in which the basic elements of this interaction are present. Our 
initial survey searched for aromatic compounds with Cl, Br, or I that are ortho  to OH or NH2  
substituents and within short distance (≤ 105% of the sum of the van der Waals radii, ΣRvdW ) of 
a XB acceptor (O or N) of an interacting compound. This analysis identified 772 complexes, 
indicating that the potential for HBeXBs is very high, even with these very limited criteria.  
A radial distribution plot of the XB donor approach to the acceptor (the θ1 -angle) showed 
that these interactions cluster around the σ -hole of the halogen (θ1 ≈  180° , Figure 3.6), as expected 
for XBs, but extend to the electronegative annulus (θ1 ≈  90° ). However, detailed analysis of the 
distance from the acceptor to the halogen (RX-A) versus the acceptor to the HB donor atoms 
(RO/N−A) shows a significant number of these contacts are primarily HB interactions to the ortho − 
OH or − NH substituents, instead of XBs to the XB donors (Figure 3.6b). With these HBs removed 
from the data set, the resulting radial analysis is even more highly clustered around the σ -hole but 
more broadly distributed across θ1 -angles (with 𝑅#X···(O/N) ≤ 1.0 and θ1 ≥  135° ) than seen in 
previous surveys of XBs (Figure 3.6c). Thus, surveys that attempt to identify XBs or HBeXBs in 
systems with neighboring HB donors using only the RX−A  as a measure must be cognizant of other 
classes of noncovalent interactions that may confound the results. It is interesting that at θ1 ≈  180°, 
the normalized XB distance (𝑅#X···(O/N) ) does not extend beyond 100% of ΣRvdW, even though the  
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Figure 3.6  
Results from survey of structures from the Cambridge Structural Database (CSD) for potential 
HBeXBs. (a) Radial distribution of potential HBeXBs. The CSD was surveyed for structures of 
halogenated aromatic compounds (Cl, Br, or I) with HB donors (OH or NH2) at the ortho-position 
that form complexes with a XB/HB acceptor (O or N). The distance from the halogen to the 
acceptor atom, normalized to the sum of the respective van der Waals radii (𝑅#X···(O/N) ≤ 1.05) are 
plotted radially relative to the angle of approach of the acceptor to the C−X bond (θ1). (b) Plot of 
normalized distances from the acceptor (A) to the halogen (𝑅#X···A) versus the distance to the HB 
donor (𝑅#  (O/N)···A). HB interactions from the acceptor to the O/N HB donor are distinguished from 
XBs from the acceptor to the XB donor by 𝑅#  (O/N)···A ≤ 1.25. (c) Radial plot of XBs from panel a, 
with HBs to the O/N HB donors removed according to the criteria in panel b. This distribution 
analysis indicates that HBeXBs fall in the range of θ1 angles from ∼135° to 180°.  
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survey extends beyond that distance, consistent with the HBeXBs being particularly strong 
interactions (assuming the strength of a noncovalent interaction is reflected in the contact 
distance). An initial survey of the Protein Data Bank with these same limiting criteria identified 
over 1000 structures with the components required to form HBeXBs, consistent with the previous 
survey by Lin and MacKerell 18. The difference, however, is that the results from our CSD survey 
now allow us to distinguish between HBs and potential HBeXBs in biomolecular structures. Thus, 
the two examples of HBeXBs found in the halide receptor and the model protein, as described 
here, are most likely not singular exceptions but simply the first experimental recognition of a 
potentially prevalent molecular interaction. 
o 3.4 Conclusions and Perspectives 
 This Account highlights the concept that a HB directly to the electron-rich region of a 
halogen augments its potential as a XB donor. The resulting HBeXB extends the stability and the 
geometry of an XB interaction, rendering it comparable and potentially stronger than a classical 
HB. While the concept of the HBeXB had previously been suggested, our studies are highlighted 
as the first direct characterization of this synergistic relationship. Our initial surveys of the CSD 
and PDB highlight the strong likelihood that HBeXBs are common in both chemical and 
biochemical molecular systems.  
Although we have now sampled HBeXBs at the two extremes of chemical complexity and 
with different pairs of XB and HB donors, there remain many aspects of polarization effects that 
are yet to be explored. For example, we expect that a stronger HB donor in these coordinated 
systems will strengthen the XB donor potential of the halogen. Similarly, the geometry of the 
HB··· X (the distance and angle of approach of the HB interaction) would affect the XB acceptor 
to donor geometry. A shorter HB, for example, would be expected to have a stronger polarizing 
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effect on the σ -hole and, thus, produce a stronger attractive force with the acceptor. Alternatively, 
the angle of approach of the HB to the halogen could affect the position of the σ -hole at the 
halogen surface, thereby affecting the approach θ1 -angle of the acceptor. Quantum calculations 
on simple model systems show that when the HB deviates from being perpendicular to the C− X 
bond (near the optimum 90°  of the electronegative center), the most electropositive point of the 
σ-hole deviates from the ideal 180°  along the C− X bond. We should note, however, that the two 
experimental systems presented here are in essentially nonaqueous environments, in an organic 
solvent or a solvent-excluded pocket of a protein. As with other noncovalent interactions, 
accessibility to water could reduce the overall potential of the HBeXB through either direct 
competition for the acceptor or, bulk solvent, by increasing the dielectric constant of the 
environment. Our research groups are studying these and other physical properties and effects on 
the HBeXB to better understand how we can rationally design the interaction for molecular and 
biomolecular engineering. 
Finally, we highlight that the HBeXB is a type of polarization-enhanced noncovalent 
cooperativity (Figure 3.7, green box, σ-bond cooperativity). As a subclass of noncovalent 
cooperativity 26,  polarization-enhanced XBs are unique: they can be polarized either directly 
through noncovalent interaction with the donor (e.g., HBeXB) or indirectly by noncovalent 
interaction with an adjacent atom that shares a σ-bond with the donor (Figure 3.7, red box). An 
example of the latter was seen in the adducts of dihalogens with heterocyclic pentatomic chalcogen 
donors, where a HB at one end of the dihalogen enhances the XB donor potential at the other end 
17.  The generality of this approach is foreshadowed by a recent computational study showing that 
intramolecular HBs also can enhance tetrel bonds (HBeTtB) in fluorosilyl and fluorogermanium 
complexes 27. The HBeXB and HBeTtB can be considered as two related subcategories of 
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polarization-enhanced noncovalent interactions (Figure 3.7 , pink and orange boxes), where HBs 
and other noncovalent interactions can cooperatively strengthen or weaken the noncovalent 
bonding of polarizable atoms (such as halogen or tetrel substituents). While this strategy is only 
now being explored, it has the potential to extend the utility of these interactions in chemistry and 






Figure 3.7  
Different types of polarization enhanced noncovalent cooperativity. The HBeXB is a subclass of 
polarization enhanced XBs where HBing directly to the XB donor enhances the XB interaction. 
EWG is an electron-withdrawing group adjacent to a HB or XB donor, while A refers to electron-
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CHAPTER 4: ENGINEERING HYDROGEN AND HALOGEN BONDS TO ENGINEER A 
SPECIFIC COILED-COIL SENSING PEPTIDE1 
 
 
o 4.1 Summary 
While the X-bond has previously been engineered into a DNA junction system and into a 
protein as an intramolecular interaction1,2, it has not yet been characterized as a protein-protein 
interaction or an intermolecular interaction. Due to the X-bond’s geometrically specific nature this 
initial engineering effort will be important to the field of biological engineering. Here we will 
address whether X-bonds can confer binding specificity and sensing ability. We will use a model 
coiled-coil system (dimerization domain of GCN4 transcription factor) as a simplified protein 
complex to address how the X-bond donor on a single a-helix can sense and specifically bind to a 
pre-existing coiled-coil dimer through the formation of an X-bond, to create a unique heterotrimer. 
By comparing our results to similarly designed heterotrimers assembling with non-specific 
hydrophobic interactions and an alternative electrostatic interaction, the H-bond, we will be able 
to determine how the X-bond compares as an intermolecular protein-protein interaction capable of 
sensing for the first time. 
o 4.2 Introduction 
o 4.2.1 Engineering Protein-Protein Interactions 
A major challenge in biomolecular engineering is to design artificial protein-protein 
interactions that show the same degree of binding affinity and specificity as oligomeric complexes 
that have evolved through natural selection3. A common scaffold for many such engineering 
 
1 Adapted from manuscript in process for submission by Rhianon Kay Rowe Hartje, Marco Ferrero, Gabriella 
Cavallo, Alessandro Gori, Pierangelo Metrangolo, and P. Shing Ho 
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efforts are the coiled-coils, naturally occurring a-helical assemblies that have been coopted for a 
variety of biomedical and material science applications 4,5. We show here that introducing either a 
hydrogen bond (H-bond) or halogen bond (X-bond) interaction into an a-helix results in a peptide 
that binds with high specificity and affinity, serving as a sensor for the dimerization domain of the 
GCN4 transcription factor.  
Recent studies have revealed the fundamental steps of the central dogma—replication, 
transcription, translation—in dramatic fashion in live cells, owing in part to the development of 
advanced tools, including ultra-resolution microscopy6. At the cellular level, molecular tools such 
as nanobodies7 that can recognize and bind to proteins or nucleic acid targets are crucial for 
labeling specific components of the cellular machinery. As such studies expand beyond visualizing 
basic steps to regulatory mechanisms 8–10, there is a need to engineer new sensing molecules, which 
in turn will require the design of new molecular (e.g., protein-protein) interactions and interfaces. 
Although artificial protein-protein interfaces have been designed computationally 11, and 
through directed evolution12, there have been only a few examples to date of success in the de novo 
engineering of new artificial protein assemblies 13. The landscape available for such engineering 
challenges, however, can be greatly expanded by extending the tool box of molecular interactions 
beyond those found in the naturally occurring amino acids to those available from non-canonical 
amino acids14. Although H-bonds are commonly seen as an interaction that provides specificity in 
biological structures and ligand binding, X-bonds have recently gained significant attention for 
molecular recognition and biomolecular engineering15,16. 
o 4.2.2 Halogen Bonds in Biomolecules 
X-bonds are analogous to H-bonds in that both present an electropositive atomic surface 
as a donor function to form a favorable non-covalent interaction with an electron-rich acceptor 
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atom (such as an O, N, or S) 17. A simple, though incomplete, theory for the root of X-bonds is the 
electrostatic s-hole model. This model posits that in forming a covalent bond with another atom, 
the pZ-orbital of a halogen substituent becomes depopulated, leaving an electron-depleted crown 
(called the s-hole) diametrically opposed to the resulting s-molecular orbital. It is this s-hole that 
provides the electropositive potential to interact with electron-rich acceptors. X-bonds are now 
recognized to play important roles in biology,18,19 including defining the recognition of 
halogenated inhibitors by their protein targets 20–24 and the design of new inhibitors against 
clinically important targets 22,25,26. We had previously engineered X-bonds into DNA junctions to 
control the molecular conformation 1 and into the classic T4 lysozyme enzyme 2 to increase its 
thermal stability and activity at elevated temperatures 16. In this study, X-bonds are introduced 
through non-canonical amino acids to engineer a specific protein-protein interaction in coiled-coil 
complexes. 
o 4.2.3 Coiled-Coils as Model Protein Engineering Platform 
We asked here whether X-bonds and H-bonds could be engineered to give specificity to 
complexes of coiled-coils—two or more a-helices that self-assemble into superhelical bundles. 
These assemblies have been broadly adapted to tackle a range of problems, including serving as 
model systems to map protein folding pathways27,28 and sequence-structure-function 
relationships29, and in the design of cavities for enzyme-substrate complexes30 and viral fusion 
inhibitors as potential therapeutics31–33. This adaptability is due in part to their predictable a-helix 
structure, which further stems from a simple repeated heptad motif of (abcdefg)n 34. The amino 
acids at positions a and d are typically hydrophobic residues, while e and g are typically charged. 
The helical repeat of ~3.6 amino acids/turn aligns the characteristic hydrophobic residues along 
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one face of the a-helix, and it is the association of the hydrophobic faces among strands that 
ultimately drives the assembly of higher-order coiled-coil bundles.  
One coiled-coil helix that has been well-studied as a design scaffold is the “leucine zipper”, 
so-called because of the regular placement of Leu at position d of the heptad repeat32,35–37. The 
~30 amino acid dimerization domain of the GCN4 transcription factor is a naturally occurring 
leucine zipper that assembles as a parallel-aligned homodimer. Changing the amino acids within 
the GCN4 heptad motif changes the topology of coiled-coil assemblies. Harbury et al., showed 
that varying the hydrophobic residue at position a while maintaining a Leu at d resulted in GCN4 
peptides that assemble as dimers, trimers, or tetramers and in parallel or antiparallel 
alignments36,38. It has been shown that the oligomerization state of coiled coil helices are controlled 
by “trigger sequences” 39. One such trigger sequence that converts the GCN4 dimer into a trimer 
involves a series of H-bonds and salt bridges among side chains that line the exterior of the coil-
coil assembly. 
For the current study, we wanted to exploit X-bonds and H-bonds for the design of a heptad 
repeat peptide that would specifically recognize and bind to a GCN4 dimer and, thus, serve 
potentially as a cellular sensor for this genetic regulator. For this challenge, we started with the 
study by Gonzalez et al., which showed that mutating an asparagine at position 16 to an alanine 
still allowed the formation of a stable GCN4 dimer40. The loss of the amide substituent of the side 
chain, however, created a ligand binding cavity that upon the addition of benzene to the system, 
the GCN4-N16A sequence assembled as a parallel trimer. In examining the structure of the 
modeled dimeric and benzene-induced trimeric states of GCN4-N16A, we observed that a 
carbonyl oxygen of the peptide backbone also became more accessible (figure 4.1), leading us to 
consider a design in which an X-bonding or H-bonding function on an aromatic side chain could  
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Figure 4.1  
The starting model for our engineering efforts. GCN4-p1 is WT with N16 to promote parallel 
dimer formation. GCN4-N16A is a less stable dimer than GCN4-p1, but the mutation creates a 
slight hydrophobic pocket and makes the carbonyl oxygen in L12 more accessible. The green will 
denote the A16-bound strand throughout the paper, and the orange will denote the A16’ strand. 
 74 
not only substitute for the benzene in filling the hydrophobic cavity, but also provide specificity 
through a non-covalent interaction. Herein we describe the successful efforts in engineering and 
characterizing heterotrimeric GCN4 coiled-coils formed by the association of this GCN4-N16A  
dimer with an a-helix monomer engineered with either a Tyr (to form an H-bond) or halogenated-
Phe (to form an X-bond) to fill the ligand cavity. We will call this third engineered peptide 
thesensing strand (ZF) of the heterotrimer. Although the peptide oxygens of both GCN4-N16A 
strands are accessible, the chirality of amino acids positions the Z substituent of the ZF strand only 
towards one of the two GCN4-N16A chains. We will distinguish this “sensed” strand as A16-
bound and the non-sensed strand as A16’ for the (GCN4-N16A)2 dimer (figure 4.1).  
o 4.3 Experimental Design 
 To carry out this study we utilized a few different techniques to better understand how 
these engineered electrostatic and hydrophobic interactions influenced the structure of the coiled-
coil. We crystallized four unique heterotrimers to glean insight in how the non-canonical amino 
acid packs in the hydrophobic core or designed “ligand binding” site of the GCN4-N16A coiled-
coil. We carried out differential scanning calorimetry (DSC) and circular dichroism (CD) studies 
to assess the thermodynamic stability and solution state of the coiled-coils. We also performed 
quantum mechanical calculations on coordinates from the crystal structure to address the energy 
change we noted from the DSC studies. 
o 4.3.1 Peptide Design and Purification 
30mer peptides (RMKQLEDKVEELLSKZYHLENEVARLKKLV) with position 16 
being A (for A16-bound and A16’ sequences), or ZF with Z being a hydroxyl group (OHF), a methyl 
group (MeF16), or iodine (IF16) were ordered crude from Biomatik and came 40-60% pure. The 
30mer sequence with 2,3,5,6-fluoro, 4-iodo-phenylalanine (TFIF16) at position 16 was synthesized 
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according to Bergamaschi et al. in the Metrangalo lab in Milan, Italy41. Lyophilized peptides were 
resuspended in 0.1% trifluoroacetic acid (TFA) in water and HPLC purified on a C18 semi-
preparative column with a gradient between 0.1% TFA in water and 0.1% TFA in acetonitrile. 
HPLC fractions containing the full-length pure peptide were dried down in a speed vacuum and 
resuspended in the appropriate buffer for the set of experiments.  
o 4.3.2 Crystallization, Data Collection, Structure Determination  
Crystallization was carried out via the hanging drop vapor diffusion method. Drops were 
prepared by mixing 2 µL of 1.46 mM peptide with 2 µL of mother liquor and allowed to equilibrate 
at 25 °C over a well containing 500 µL of mother liquor. The 1.46 mM peptide was prepared in a 
2:1 ratio of GCN4-N16A:GCN4N16-ZF16, with ZF being 2,3,5,6-fluoro, 4-iodo-phenylalnine 
(TFIF16), 4-methyl-phenylalnine (MeF16), 4-iodo-phenylalanine (IF16), or tyrosine (OHF16) in 10 
mM potassium phosphate, 100 mM potassium chloride pH 7.0. Crystals were obtained for all of 
the constructs in mother liquors ranging from 0.9-1.1 M sodium citrate and 90-110 mM HEPES 
pH 7.0. Crystals were looped, flash frozen in liquid nitrogen and mounted, so data could be 
collected from the crystal on the Rigaku Compact Home Lab with a PILATUS detector (figure 
4.2). HKL2000 was used to index, integrate, and scale the data. The phase of the structures was 
determined with molecular replacement [using the GCN4-N16A trimer as the starting search 
model (PDB 1SWI)] and refined using Phenix.  
o 4.3.3 Melting Profiles Determined with Differential Scanning Calorimetry  
DSC samples were prepared by mixing GCN4-N16A with GCN4-N16-ZF16 in a 2:1 ratio 
at 0.54 mM in 100 mM sodium chloride, 50 mM HEPES pH 7.0. The data were collected on a TA 
instruments Nano DSC. Thermal scans were set-up from 5°C to 105°C at a rate of 1°C /min at a 













Figure 4.2  
Representative crystals that were looped and data collected from for each of the four crystal 
structures determined. All crystals indexed to the same space group (C121) with similar unit cell 
dimensions and angles.   
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melting (DHM) were determined by fitting the data with TA Nano Analyze software, using a two-
state scaled model. At least 4 replicate measurements were conducted for each construct. The 
average and standard deviation were calculated and reported from the 4 replicates. An entropy of 
melting (DSM) for each scan was calculated from the TM and DHM, as DSM = DHM/TM. 
o 4.3.4 Circular Dichroism Spectroscopy Titration  
CD spectra were obtained on a Jasco spectrometer J-1000 and analyzed with Spectrum 
Manager. A titration of increasing GCN4-N16ZF16 to GCN4-N16A was carried out in order to 
assess the ratio of the two sequences that formed a stable coiled-coil in solution. Titration points 
included ratios of GCN4-N16A: GCN4 N16-ZF16 of 1:0, 10:1, 7:1, 5:1, 4:1, 3:1, 5:2, 2:1, 3:2, 1:1, 
1:2 and 1:3. The  De at 208 and 222 nm were monitored and their ratio (222/208) was calculated 
from the spectra to indicate higher ordered coiled-coil formation. 10 scans were carried out and 
averaged for each titration point, and each titration was done in triplicate. Scans were taken from 
190 nm to 300 nm over 50 nm/min. Samples were prepared by mixing the appropriate ratio of 
GCN4-N16A to GCN4-N16-ZF16 to a volume of 500 µL and 50 µM in 5 mM HEPES pH 7.48 
and placed in a 1mL cuvette for data collection.  
o 4.3.5 Quantum Mechanical (QM) Calculations 
The atomic coordinates from the crystal structures were taken from the interacting residues 
(A16 and L12 from one chain, and ZF16 from alternate chain) and were simplified down to 2 N-
methyl-acetamide molecules (A16 and L12) and a benzene mimicking the ZF aromatic residue. An 
AM1 geometry optimization on the hydrogen atoms was performed on the complex prior to energy 
calculations. For energy calculations, Møller-Plesset second-order (MP2) level of theory with the 
aug-cc-PVTZ (aug-cc-PVTZ-PP from EMSL basis set exchange for IF16 and TFIF16) basis set was 
used in cyclohexane (D=2 compared to vacuum) to mimic the hydrophobic interior of the coiled-
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coil. Basis set superposition error (BSSEs) calculations were also carried out and summed into the 
solvent phase energy.  
o 4.4 Results 
 The objective of the current study is to engineer a peptide that specifically recognizes and 
binds to, or senses, a variant of the GCN4 dimerization domain to form a heterotrimeric coiled-
coil assembly. For the current study, we have designed a sensing peptide strand that is based on 
the GCN4 leucine zipper, but with a substituted phenylalanine (ZF, where Z is an -OH, -I, or methyl 
(Me)) incorporated to provide binding affinity and specificity. The ZF is expected to fill the 
hydrophobic cavity created in a mutant of the GCN4 dimerization domain in which the Asn residue 
at position 16 is replaced by an Ala (GCN4-N16A) and provide specificity through an H-bond or 
an X-bond to the now accessible carbonyl oxygen of the polypeptide backbone (figure 4.1). The 
GCN4-N16A is combined with a GCN4-N16 ZF peptide in a 2:1 ratio in order to form a potential 
heterotrimeric complex (table 4.1). The assembly of the predicted heterotrimeric coiled-coils and 
the role of the H- or X-bonding interaction are characterized in the single-crystal structures of the 
complexes (figure 4.3). In addition, the structures provide the detailed geometries of the ZF 
substituent interaction with the carbonyl oxygen of the L12 peptide backbone, along with other 
near-neighbor interactions, in order to assess the potential formation of X- or H-bonds. Of 
particular interest are the distances (dZ···O) and the angle of approach (q1) of the Z substituent to the 
carbonyl oxygen of L12. The oligomeric states of the assemblies were characterized in solution 
from the thermal melting parameters determined by differential scanning calorimetry (DSC) and 










The abbreviations of the strands referred to throughout and the sequences of the respective strands 
used for all the experiments carried out. The 30mer sequence is derived from the dimerization 
domain of the GCN4 transcription factor. All of the sequences are identical expect for position 16 





A16’ – GCN4 N-RMKQLEDKVEELLSKAYHLENEVARLKKLV-C 
A16 – BOUND – GCN4 N-RMKQLEDKVEELLSKAYHLENEVARLKKLV-C 
OHF – GCN4 N-RMKQLEDKVEELLSKOHFYHLENEVARLKKLV-C 
IF – GCN4 N-RMKQLEDKVEELLSKIFYHLENEVARLKKLV-C 
TFIF – GCN4 N-RMKQLEDKVEELLSKTFIFYHLENEVARLKKLV-C 
MeF – GCN4 N-RMKQLEDKVEELLSKMeFYHLENEVARLKKLV-C 
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Figure 4.3  
A zoom in on the electrostatic or hydrophobic interaction taking place between the ZF strand and 
the A16-bound strand. a) The H-bond that forms between the OH on the tyrosine and the L12 
carbonyl oxygen in the A16-bound chain. b) Rotamer A in the TFIF16 structure (73% occupancy) 
with the X-bond to the carbonyl oxygen.  c) Rotamer B in the  TFIF16 structure (27% occupancy) 
with the X-bond shown. d) Shows the shallow angle of approach the iodine in IF16 has to the 
carbonyl oxygen while e) shows the similar interaction the methyl group in MeF16 has. 
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The specificity and affinity afforded by a classical H-bond was evaluated through an 
engineered tyrosyl (GCN4-N16OHF) sensing strand. The ability of an X-bond to substitute for an 
H-bond will be compared for an iodinated-Phe (GCN4-N16IF) construct, which has a strong but 
standard s-hole, and a unique para-iodotetrafluoro-Phe (GCN4-N16F4IF) unnatural amino acid, 
where the electron-withdrawing fluorines greatly enhance the s-hole of the iodine to create an 
unusually strong X-bond donor 41. Finally, the role of steric interactions and hydrophobic effects 
on the sensing peptide will be assessed using a methyl-Phe construct (GCN4-N16MeF). 
o 4.4.1 Crystal Structures of (GCN4-N16A)2/GCN4-N16ZF Heterotrimers 
  Mixtures of GCN4-N16A with GCN4-N16ZF in 2:1 ratios all formed isomorphous crystals 
and their X-ray diffraction structures determined to 1.8Å to 2.3 Å resolution. All of the structures 
of these complexes were seen to be (GCN4-N16A)2/GCN4-N16ZF heterotrimers, with the peptides 
in parallel alignment (figure 4.3). In each structure, the cavity at the A16 position is filled by the 
aromatic side chain of the ZF amino acid from the GCN4-N16ZF peptide. The specific or non-
specific interaction of the side chain with GCN4-N16A depends on the identity of substituent Z. 
The structure of the GCN4-N16OHF construct showed the formation of an H-bond from the 
hydroxyl of the tyrosine to the carbonyl oxygen of the peptide backbone at position L12 of the 
A16-bound strand of the dimer. The O···O distance and q1 angle is near the standard geometries 
for an H-bond (table 4.2). The expectation, therefore, is that this would be a fairly strong interaction 
that can provide specificity of the engineered ZF-strand for the (GCN4-N16A)2 dimer.  
We next asked whether an X-bond could substitute for the OH H-bond of the ZF-strand with 
a GCN4-N16IF construct. The structure of this (GCN4-N16A)2/GCN4-N16IF construct showed 
that the iodine was also positioned towards the carbonyl oxygen of L12 of the A16-bound strand 













Table 4.2  
Bond geometries from the crystal structures. The Z --- O distance with the calculated percent of 
the sum of van der Waal radii and the angle of approach the Z substituent takes to the carbonyl 
oxygen (q1) is noted.   
CONSTRUCT (ZF STRAND) RZ---O (%SRVDW) q1 
OHF16 – GCN4 3.1 Å (101%) 132° 
IF16 – GCN4 3.1 Å (88%) 112° 
TFIF16 – GCN4 (ROT A) 2.9 Å (83%) 135°  
TFIF16 – GCN4 (ROT B) 3.2 Å (91%) 136°  
MEF16 – GCN4 3.3 Å (94%) 128° 
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van der Waals radii, ∑RvdW), the shallow q1 angle of approach was not consistent with an X-bond 
(table 4.2). A quantum calculated electrostatic surface potential (ESP) map of iodobenzene (a 
model for the IF side chain) indicates that a q1 angle < 145° would point the oxygen acceptor 
towards the electronegative surface of the iodine (figure 4.4), which would not be a stabilizing 
interaction. The additional interactions of the iodine with carbons of various side chains in the 
cavity suggests that the halogen is behaving as a non-specific hydrophobic substituent and less as 
a donor in a specific electrostatic-type interaction. To test this hypothesis, we characterized the 
crystal structure of the GCN4-N16MeF16 construct, where a hydrophobic methyl group replaces 
the iodine (RvdW ~2.0 Å for methyl compared to 1.98 Å for iodine). In comparing the MeF16 and 
IF16 structures, we noticed the rings and the methyl and iodine of IF and meF nearly perfectly 
superimposed. The similarity among these structures suggests that the behavior of the iodine is 
structurally similar to that of the methyl group in this system, and that an iodine X-bond could not 
substitute for the OH H-bond of the tyrosine in the GCN4-OHF construct. 
The X-bonding potential of a halogen substituent can be enhanced through inductive effects 
from electron-withdrawing groups, such as fluorine. We thus engineered an ZF peptide with a 
2,3,5,6-fluoro-4-iodo-phenylalanine (TFIF) in place of the N16 residue, creating a GCN4-TFIF 
construct. The ESP surface map of a 2,3,5,6-fluoro-4-iodobenzene model of the TFIF side chain 
shows that the charge neutral point of the iodine is now extended to a q1 angle ≈ 125°, which can 
accommodate a much shallower approach of the oxygen acceptor to the s-hole of the halogen 
(figure 4.4). The crystal structure of the GCN4-TFIF construct was again a heterotrimer, with the 
TFIF seen to occupy two rotamer positions. The major rotamer (A) shows a 73% partial occupancy, 




Figure 4.4  
Electrostatic potential maps of small molecule mimics of IF (I-Benzene) and TFIF (TFI-benzene). 
With the replacement of hydrogens for 4 fluorines on the aromatic ring, the s-hole of the halogen 
gets much bigger. With this enlargement, the angle of approach an acceptor atom can take widens 
from 145° to 125°.  
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the plane of the B-rotamer’s aromatic ring is similar to that of the OHF , IF , and meF side chains, 
but that of rotamer A is rotated ~75°. The iodines in both positions are in geometries compatible 
with the formation of X-bonds to the carbonyl oxygen of L12 of the A16-bound strand. The B-
rotamer shows a slightly longer dZ···O relative to the A-rotamer, while the q1 angles are about the 
same (table 4.2). It is not possible from the structure alone to determine which interaction is 
stronger, and how either compares to the OH H-bond seen in the GCN4-OHF construct. To better 
understand how the specific H-bond and X-bond and non-specific hydrophobic interactions at this 
site 16 influence the coiled-coil’s overall stability, we carried out differential scanning calorimetry 
studies.  
One structural difference in the (GCN4-N16A)2/GCN4-N16TFIF trimer and that of the other 
complexes is that the intramolecular i-i+4 H-bonds along the a-helix backbone is elongated from 
the average 1.5-3.1 Å to 3.5 Å (which is no longer an H-bond) between residues 14 and 18 of the 
A16-bound peptide. Thus, there is a local unwinding of the helical backbone in order to 
accommodate this larger TFIF side chain and its two rotamers.  
o 4.4.2 Thermal Melting Parameters from Differential Scanning Calorimetry 
The crystallographic studies suggest that the (GCN4-N16A)2/GCN4-N16ZF heterotrimers 
fall into two classes. The Z = OH or TFI involve electrostatic H- or X-bonds and are expected to 
provide specificity to the A16-bound peptide for the GCN4-N16A dimer. The Z = I or Me are 
involved in non-specific hydrophobic interactions and, therefore expected to be non-specific. The 
question at this point is how these predictions from the crystal structures are manifest in solution. 
We first attacked this question by comparing the DSC-determined thermal melting behavior for 
each set of complexes, without any preconceived idea as to their oligomeric state.   
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We started the DSC studies by determining the melting temperature (TM) and melting 
enthalpy (∆HM) of the GCN4-N16A construct, which was previously shown to form a homodimer 
in solution4 0. The resulting DSC thermal melting curve was fitted with a simple two-state melting 
process (figure 4.5). The TM measured by DSC in this study is nearly identical to the previously 
published value of 62.2 °C 40 and, therefore, we are confident that the GCN4-N16A construct is 
also a dimer. 
Addition of the GCN4-N16OHF strand resulted in a thermal melting curve that was very 
similar to the GCN4-N16A dimer, and similarly fitted with a two-state model with random 
residuals. Thus, the 2(GCN4-N16A) + GCN4-N16OHF mixture appears to be homogeneous in 
forming a single species. The TM is increased by 16.3° C, while the ∆HM and resulting ∆SM are 
52% and 38% higher, respectively, than the GCN4-N16A dimer (figure 4.5, table 4.3). These 
results are consistent with this mixture forming a (GCN4-N16A)2/GCN4-N16OHF heterotrimer. 
The 2(GCN4-N16A) + GCN4-N16TFIF mixture shows the same melting profile as that with 
the GCN4-N16OHF strand, with the TM increased by 16.1° C, while the ∆HM and ∆SM are both 
~44% higher than the GCN4-N16A dimer (table 4.3). The DSC analysis are, thus, also indicative 
of a homogeneous species that can be assigned as a (GCN4-N16A)2/GCN4-N16TFIF heterotrimer. 
The TMs for the mixtures of 2(GCN4-N16A) + GCN4-N16ZF (where Z = I or Me) were 
shifted to even higher temperatures but could not be fitted to a simple two-state model without 
significant residual errors (supplemental figure 1 in Appendix I). These data were interpreted as 
being heterogeneous mixtures of oligomers and, therefore, the melting parameters were not 
analyzed in detail.  
The DSC results show that the Z = OH and TFI constructs both form single heterotrimeric 




Figure 4.5  
Buffer-subtracted and baseline-subtracted representative melting profiles obtained for the A16 
dimer, OHF16 heterotrimer and TFIF16 heterotrimer. A clear shift is seen between the dimer and 
trimer species with a significant increase in TM. All of the data for these species were fit to a 












Table 4.3. Thermodynamic data obtained from DSC experiments. The TM and enthalpy (DHM ) are 
found with the two-state fit, while the DSM  is calculated from those two values using the equation 
DG = DH - TDS. The averages and their respective standard deviations from the 4 replicate runs 
are reported in the table.   
CONSTRUCT TM (°C) DHM (KCAL/MOL) DSM (KCAL/MOL • K) 
A16 64.4 ± 1.1 32.9 ± 1.8 97.7 ± 5.3 
2:1 A16: OHF16 – GCN4 80.7 ± 0.7 50.0 ± 1.9 134.4 ± 4.8 
2:1 A16:TFIF16 – GCN4 80.5 ± 0.9 47.5 ± 1.7 141.1 ± 5.4 
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state. We interpret these results as indicating that hydrophobic interactions in themselves are not 
sufficient to result in a single unique assembly, but that the electrostatic H- and X-bonds provide 
the specificity required to assemble a unique trimeric complex. The ~2 kcal/mol higher ∆HM for 
the GCN4-N16OHF complex over GCN4-N16TFIF complex suggests either that the H-bond is 
slightly more enthalpically stabilizing than even the highly polarized X-bond, or that the loss of 
the H-bond in the local unwinding of the GCN4-N16TFIF helix has a slight destabilizing effect on 
the complex, or both.  
The ~7 cal/mol·K higher ∆SM for the iodo construct suggests that the difference in enthalpic 
energy is compensated by a gain in entropy, resulting in nearly identical TM values for the two 
heterotrimers. We interpret the increased entropy contribution to the TFI construct as coming from 
burying the hydrophobic halogen into the cavity of the trimer interface, rather than from 
conformational entropy. An analysis of the normalized crystallographic temperature factors (B-
factors) for the GCN4-N16A, and the Z = OH and TFI trimers shows that the X-bonded complex 
shows a higher B-factor Ser14, associated with the slight unwinding of the local helix to 
accommodate the larger TFIF16 side chain and its two rotamers (figure 4.6). If the entropic 
difference were conformational, we would have predicted that ∆SM would be lower for the X-
bonded trimer. 
o 4.4.3 Heterotrimer Formation Determined by CD Spectroscopy Titrations 
Although the DSC studies indicated the Y16 and TFIF16 coiled-coils assembled exclusively 
as heterotrimers in solution, the melting parameters did not provide information on the specificity 
or the stability of this complex at room temperature. In order to estimate the affinities of the ZF 
strands for the GCN4-N16A dimer, we titrated the ZF strand into solutions of the A16 dimer. The 




Figure 4.6  
B-factor analysis on the OHF16 and TFIF16 structures. The B-factors for all of the backbone atoms 
(N, Ca, C, O) in Leu 12 – Ala16 /ZF16 in the three chains were averaged and set to 100%. The 
backbone atoms in the individual residues were then normalized to that average value, and the 
average of the four normalized values is reported. The error bars are the standard deviation of the 
mean. While most of the values are below the average value (100%), the A16-bound strand in the 
TFIF16 structure has a very high B-factor associated with Ser14 associated with the local unwinding 
(loss of i—i+4 H-bond) in the helix to accommodate the large TFIF ring.  
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CD spectra at each titration point is indicative of formation of superhelical oligomers, without 
preconception of the number of strands in the assemblies. At each titration step, the total 
concentrations of peptides were held constant at 50µM (10-fold lower than the DSC studies), while 
varying the ratio of the ZF strand to the A16 dimer. 
The CD titrations with the MeF16 peptide resulted in data that asymptotically approached a 
maximum at 0% A16 peptide. This binding curve is consistent with a low affinity binding process 
(figure 4.7d) and was interpreted as evidence the MeF16 peptide forms a superhelical homodimer 
with a KD ≈ 43 µM. The CD titration curve for the IF16 strand showed the same homodimerization 
behavior, with a KD ≈ 14 µM (figure 4.7c). 
The CD titration curve for the TFIF peptide, however, was more complex, with the 
∆(De220nm/De208nm) increasing nearly linearly from a TFIF16 to A16 ratio of 0:2 to 1:2, then falling 
and then rising again (figure 4.7b). Our interpretation is that the first component is a high affinity 
binding of the TFIF16 to A16 dimer to form the heterodimer at a 1:2 ratio, with TFIF16 being 
limiting. The drop in the superhelicity after the 1:2 ratio comes from loss of the heterotrimer as the 
A16 strand becomes limiting, leaving excess TFIF16 strand in solution. As the TFIF16 concentration 
continues to increase, this peptide forms its own superhelical homodimer. This behavior can be 
modeled as two competitive binding events, with the formation of the heterotrimer having an 
apparent KD ≤ 10 nM, and the TFIF16 homodimer having a KD ≈ 5.5 mM.  
The titration of the OHF peptide into the A16 dimer resulted in a curve that is nearly identical 
to that of TFIF16 (figure 4.7a), with apparent KD ≤ 10 nM, and the OHF16 homodimer having a KD 
≈ 6 mM. The KD for the heterotrimer is considered to be an apparent value, since although the 
simplest model assumes that the TFIF16 or OHF binds to a preformed A16 dimer, it is possible that 






Figure 4.7  
CD titration of ZF strand into A16. The fractional change of ellipticity at 222 nm versus 208 nm 
calculated from the CD spectra is plotted against fraction of helices formed or the ratio of ZF16 to 
A16. While A16 is kept constant, it acts as a “limiting reagent” in solution. Once it is all bound 
up, in the case of OHF16 and TFIF16, those strands begin to be in excess and start dimerizing with 
themselves. As MeF and IF do not bind A16 at this low concentration, they just dimerize with 
themselves throughout the titration. a) Titration results for OHF16. The ratio ellipticity climbs 
quickly and once a ratio of 1:2 OHF16:A16 is met (heterotrimer formation), the slight dip down in 
the ratio ellipticity and subtle increase indicates the homodimer formation. Similar results are seen 
in b) with the TFIF16 titration. c) shows the titration results for IF16, while d) shows similar results 
when MeF16 is titrated into A16.  
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o 4.5 Discussion 
We have shown with this study that a highly stable heterotrimer coiled-coil complex can 
be designed with an intermolecular electrostatic interaction to the peptide backbone, providing 
specificity to the complex. Single crystal structures show that the iodine of the unnatural amino- 
acid TFIF forms a short X-bond, while the hydroxyl of the analogous OHF construct forms a near 
ideal H-bond to the peptide oxygen of a neighboring strand. The substituent groups of IF and MeF 
sit in the same pocket formed in the A16 dimer; however, these structures suggest that the 
interactions are primarily van der Waals interactions and, therefore, may not provide the specificity 
afforded by the X- and H-bonding interactions. 
CD titration studies support the predictions for specificity from the crystal structures. Both 
the TFIF and OHF constructs were seen to form complexes at ratios of 1:2 ZF:A16, consistent with 
stable heterotrimers, while the IF and MeF peptides formed only homodimers at these low 
concentrations. The specificity comes from both the high affinity of the X- and H-bonding peptides 
with the A16 dimer and low affinity for themselves, thereby, lowering the probability of forming 
homodimers compared to the IF and MeF peptides. 
In the DSC studies, it is clear that all constructs mixed in 1:2 ZF:A16 formed heterotrimers, 
which is not surprising since these studies were performed at ~10-fold higher concentrations for 
all species than for the CD studies. These results suggest that the KD for the binding of IF and MeF 
strands to the A16 dimer is between 50µM and 500 µM. Although explicit thermodynamic melting 
parameters could not be determined for these two constructs, we show that a melting profile for 
the IF homodimers could be derived as the residual after subtracting the TFIF:A16 heterotrimer and 
A16 homodimer profiles (supplemental figure 2 in Appendix I). Thus, it appears that the shift in 
the IF:A16-trimer melting profile to higher temperatures compared to the TFIF and OHF constructs 
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is likely due to the presence of significant quantities of IF homodimer and not a result of a more 
thermally stable trimer or presence of higher order structures. 
The crystallization of each construct was at millimolar concentrations and, therefore, 
follows the trend of increasing the probability of heterotrimer formation as the concentrations of 
material increases. Thus, the oligomeric states of the IF and MeF constructs are concentration 
dependent, forming homodimers at the lower concentrations and heterotrimers at high 
concentrations of the peptides, while the TFIF and OHF constructs favor the heterotrimers at all 
concentrations, reflecting the specificity provided by the X- and H-bonds, respectively. 
Although the TFIF and OHF heterotrimer complexes show similar melting profiles and TMs, 
they reach that point from different thermodynamic routes. The OHF complex is stabilized primarily 
from enthalpic contributions, while the TFIF complex shows additional contributions from entropic 
stabilization of the heterotrimer. The difference of 2.5 kcal/mol in enthalpic stabilization for OHF 
over TFIF can be attributed to the electrostatic X- and H-bonds. This interpretation is supported by 
quantum mechanical (QM) calculations on the interacting components of these assemblies. For 
these calculations, we constructed ternary complexes of small-molecule mimics, consisting of a 
hydroxybenzene or tetrafluoroiodobenzene (representing the OHF and TFIF side chains, 
respectively), an N-methylacetamide (NMA) to represent the L12 peptide backbone that provides 
the carbonyl oxygen acceptor for the H- or X-bond, and a second NMA that is H-bonded to the 
L12 peptide. The components were placed in positions as defined by the crystal structures, with 
hydrogens added and positioned through QM optimization. The overall energies of the resulting 
complexes showed that the OHF complex is 2.4 kcal/mol more stable than the TFIF assembly, with 
the energy of the latter weighted according to the proportion of the two conformations seen in the 
crystal structure (figure 4.8). The contribution of each interaction within the ternary complex can  
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Figure 4.8  
Quantum mechanical calculation set-up. Coordinates from L12 and A16 in the A16-bound strand 
were pulled from the crystal structure and adapted to N-methyl-acetamide (NMA) molecules. 
Coordinates from ZF were also pulled and adapted to a benzene small-molecule mimic. Energy 
calculations on each individual piece were carried out and then subtracted from the energy 
calculation on the ternary structure to get the overall energy of the complex. The energy of the H-
bond and X-bonds alone were calculated in a similar fashion.  
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be estimated by systematically calculating the pair-wise energy. The pair-wise energies, again, 
show that the H-bond of OHF is ~3.6 kcal/mol more stable than the weighted X-bond of TFIF. 
The compensatory entropic stabilization of the TFIF heterotrimer can come from higher 
conformational or solvent entropy compared to the OHF complex. The conformational entropy  
could, for example, reflect the two conformations seen for the TFIF side chain, while the solvent 
entropy would be associated with burying its more hydrophobic side chain. In order to determine 
the contribution of conformational entropy, we normalized the B-factors of the two structures and 
compared the thermal factors for each of the interacting amino acids (figure 4.5). From this 
analysis, it is clear that the B-factors of the TFIF complex are much higher than the comparable 
residues in OHF, suggesting that the interactions of the larger TFIF amino acid actually makes this 
region of the complex more dynamic overall. Thus, we would expect the change in entropy during 
unfolding to be lower for TFIF versus OHF, which is the opposite of what is observed from the DSC 
studies. 
The IF and MeF constructs, however, show that hydrophobicity without the H- or X-bond 
interaction is not sufficient to provide the same level of stability to the heterodimer, particularly 
over their homodimeric forms. 
This is the first study, to our knowledge, that engineers electrostatic interactions in the 
interior of a hydrophobic coiled-coil to test their ability to assemble hetero-oligomeric complexes. 
More specifically, this is the first time an X-bond has been purposefully designed to create a new 
protein-protein interaction. Coiled-coil assemblies have been the prototype for demonstrating the 
power of the “knobs-in-holes” concept for the design of intermolecular protein-protein 
interfaces42,43. 
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In this study, we demonstrate that designing a cavity for an aromatic amino acid that also 
exposes the peptide backbone in a hole provides unique specificity that goes beyond classic 
hydrophobic effects.  
The GCN4 coiled-coil that serves as the framework system for this study provides clear 
potential applications for the H- or X-bonding peptides characterized here. It would be interesting, 
for example, to apply these peptides as specific inhibitors to control GCN4 activated gene 
expression. As a “master” regulator, GCN4 controls ~10% of all genes in yeast, including those 
associated with protein synthesis and lifespan 44. An alternative application would be as a cellular 
probe for localizing GCN4 regulation sites along the DNA and transcription of the genes 
associated with these sites. 
The ability to assemble different helical peptides into heterotrimeric complexes allows us 
to design systems that bring multiple components together in a specific manner for bioengineering 
applications. Finally, the concepts developed here of constructing highly specific “knobs-in-holes” 
interfaces can be applied to control homo- or hetero-oligomerization states in a wide variety of 
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CHAPTER 5: HYDROGEN BOND ENHANCED HALOGEN BONDS TO INCREASE 
YEAST KIX DOMAIN STABILITY 
 
 
o 5.1 Summary 
 In this study, we have site-specifically incorporated unnatural amino acids (meta-halo-
tyrosines) into yeast KIX, a protein with an intrinsically disordered region, to better understand 
how the formation of a Hydrogen Bond enhanced Halogen bond (HBeXB) can affect this class of 
proteins stability and function. This in vitro characterization of engineered yeast KIX will show 
how the HBeXB can provide up to ~4 kcal/mol of stabilizing potential while minimizing structural 
perturbations. As structure determines function in the cell, probing how slight structural and 
energetic changes affect these proteins’ (with intrinsically disordered regions) function will be 
beneficial as these proteins can be associated with cellular dysfunction, so stabilization could be a 
means to combat some of the unwanted side effects that complement their structure. 
o 5.2 Introduction 
Proteins that participate in many functions and bind a plethora of factors in the cell often 
have intrinsically disordered regions, as this state allows them to adopt an assortment of 
conformations to carry out their various tasks 1. While this feature is crucial for their role, the 
instability inherent in this lends these proteins prone to misfolding or aggregating, having a shorter 
half-life as disordered regions are susceptible to proteasome degradation 2, and if their expression 
levels are not tightly regulated, the abundance of the low-affinity transient interactions they make 
could lead to off-target interactions which may lead to disease states 3. More so, cancer cells benefit 
from the capacity of these disordered proteins to form assemblages leading to cellular 
dysregulation4. 
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While stabilization of such proteins seems like an “easy” fix to prevent these damaging 
effects to the cell, on the contrary, locking these proteins into a particular conformation may force 
them into a certain cellular pathway or prevent them from operating in another crucial pathway. 
The increased stability may increase binding to certain targets or eliminate binding to others.  The 
structural flexibility innate to these proteins is what defines their cellular function. So, how might 
their function alter upon stabilization? On a broad scale, how will cells respond to a stabilized 
version of a protein? In thinking about these proteins as potential therapeutic targets, due to some 
of the detrimental effects that accompany their structure, could stabilization be a beneficial strategy 
to combat some of the effects or will other cellular issues ensue from the presence of the stabilized 
protein?  
o 5.2.1 KIX Domain 
Before tackling these larger questions, we must first choose an appropriate protein to 
stabilize and carry out in vitro experiments to evaluate its engineered stability and function. As 
such, we elected to work with the KIX domain of the yeast Gal11p complex, a mediator of RNA 
polymerase II transcription subunit 15 (MED15) involved in transcription of specific genes 5. The 
KIX domain is thought to be one of the most important molecular recognition sites for gene 
regulation as it’s required in the assembly of the transcriptional apparatus in not only yeast, but 
mammals as well. In yeast, KIX interacts with a range of transcription factors including Gal4p, 
Gcn4, Pdr1/3, and Oaf1, to name a few 5. It is a key part of the pleiotropic drug response pathway 
in yeast as it activates transcription of genes that work to pump toxic compounds/antifungals out 
of the cell (figure 5.1). As such, it is a clinical target in combatting antifungal resistance 6. While 
a solution NMR structure of KIX exists 7, no crystal structure of it in its apo state has been solved. 
However, several crystal structures of the domain bound to certain factors do exists8–10. While the  
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Figure 5.1  
Pleiotropic drug efflux pathway KIX is involved in in yeast. Pdr1p (Pleiotropic Drug Response 
Protein 1) binds its enhancer (PDRE), and antifungals/toxic compounds come and bind Pdr1p, 
which then binds KIX in the mediator complex. The mediator can then bind the C-terminal domain 
of Polymerase II to activate transcription of drug efflux genes. These genes then work to pump the 
toxic compounds/antifungal treatments out of the cell. 
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yeast KIX structure, according to the NMR results, closely resembles the mammalian KIX 
structure (figure 5.2), a three-helix bundle, the sequences are only ~25% homologous. 
o 5.2.2 Engineering with HBeXBs 
In regard to how to stabilize this protein, our goal is to maximize the increase in stability 
with minimal change to the protein sequence. By not adjusting the protein’s primary sequence so 
much, we hope to minimally disturb the overall fold of the protein, so its entire function is not 
obliterated.  
We previously engineered a hydrogen bond enhanced halogen bond (HBeXB) into T4 
lysozyme and found with a single mutation (Y18 to mClY18) the enzyme had increased thermal 
stability, activity, and an increase in enthalpy of unfolding of ~3 kcal/mol compared to WT 11. 
These increases came from the addition of a single atom (Cl) to the sequence that participated in a 
very strong HBeXB in the structure. As this study showed the amount of energy you can harness 
with the incorporation of a single atom oriented properly to make a stabilizing HBeXB, we sought 
to apply this same engineering strategy to yeast KIX. There is a tyrosine conserved across multiple 
KIX domains (yeast, mouse, and human) that appears to be making an H-bond with a carbonyl 
oxygen in a1, which is thought to be an intrinsically disordered region12. The tyrosine is in the 
hydrophobic core of the helix bundle near the N-terminus of the protein in a3. Due to its 
conservation and placement (figure 5.2), this is the tyrosine we have chosen to replace with a meta-
halogenated-tyrosine (mXY). With this study on an engineered yeast KIX protein, we also aim to 
show the progression of enthalpic stability derived from the incorporation of meta-chloro and 
meta-iodo-tyrosine into yeast KIX. This will allow us to better understand the tunability of the 
HBeXB in a protein framework as well. 
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Figure 5.2  
Structural alignment of Yeast KIX (orange PDB: 2k0n) and Mammalian KIX (cyan PDB: 2agh). 
While the sequences are only ~25% homologous, they both have the same three-helix bundle core. 
Mammalian KIX has two additional 310 helices.  One near the N-terminus, and the other between 
a1 and a2. The tyrosine at 66 lies in a3 and is one of the few residues conserved across species.  
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In considering our overall goal of understanding how stabilized proteins may affect overall 
cellular function, the first step is engineering a more stable protein. We expect the HBeXB 
engineering route will allow us to enthalpically stabilize yeast KIX while not altering its overall  
fold significantly. We anticipate the minimal change in primary sequence to be reflected as a slight 
structural change. However, even slight structural changes can make a big impact in terms of 
function. To glean insight on how the engineered KIX protein’s function or activity may alter in 
vitro, we have opted to work with one of its binding partners, Pdr1p. 
o 5.2.3 Pdr1p Binding Partner 
Pdr1p is a transcription factor that regulates the pleiotropic drug response13. It is a zinc 
cluster protein involved in regulation of multidrug resistance genes. It is thought that xenobiotics 
bind a ligand-binding domain of Pdr1p, which then allows the activation domain of Pdr1p to bind 
KIX, a part of the mediator complex. The mediator then interacts with the C-terminal domain of 
Pol II to recruit Pol II to transcribe genes encoding drug efflux pumps 13 (figure 5.1). This is a 
mechanism in yeast responsible for multidrug resistance as the drug efflux pumps propel antifungal 
drugs out of the yeast, rendering them useless. As the binding of KIX to Pdr1p is a crucial part of 
this pathway, examining how the engineered KIX mutants bind this partner will be an informative 
first step for evaluating if and how one of the protein’s functions has been affected in vitro. We 
will be using a 12mer peptide from Pdr1p for this study (Pdr1p-12mer) that was previously found 
to bind KIX and induce structural changes from an NMR titration 13. 
o 5.2.4 Summary of Study 
In this study, we have engineered a meta-chloro-tyrosine and meta-iodo-tyrosine into yeast 
KIX, a protein with an intrinsically disordered region, and carried out initial biophysical 
experiments (DSC and CD) characterizing the engineered proteins in vitro. In applying HBeXB 
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engineering efforts to this protein we will be able to address 1) how the meta-halo-tyrosines affect 
yeast KIX’s structure, 2) if the meta-halo-tyrosine can stabilize the protein, and 3) how meta-halo-
tyrosine influences one of KIX’s functions – binding to Pdr1p-12mer. Answering these questions 
through an in vitro analysis will be an important first step for future in vivo experiments.  
o 5.3 Experimental Section 
 To carry out the in vitro characterization, we first engineered the KIX proteins containing 
meta-chloro and meta-iodo-tyrosine through non-canonical amino acid incorporation. We then 
carried out circular dichroism and differential scanning calorimetry studies to test the mutant’s 
secondary structural changes, stability, and binding potential compared to WT KIX.  
o 5.3.1 Protein expression  
All KIX constructs started from the yeast KIX gene, with a 6-His tag appended to the C-
terminus for purification ease (figure 5.3). The WT KIX gene was ordered from Geneblock codon 
optimized in a pET26 vector, which bears a kanamycin resistance gene. The plasmid used for non-
canonical amino acid incorporation was generated from site-directed mutagenesis of the WT 
plasmid. The codon from Y66 (TAC) was changed to the amber stop codon (TAG) (so a C to G 
mutagenesis), which is the codon most typically utilized for non-canonical amino acid 
incorporation14 . 
WT KIX plasmid was transformed into BL21 codon plus E. coli. cells via heat shock at 
42°C for 20 seconds.  1 µL of 5 µg/µL of WT KIX plasmid was added to 75 µL of thawed BL21 
codon plus cells. The cells sat on ice for 20 minutes after addition of the plasmid and then 
underwent heat shock to open up the cell walls to allow the plasmid into the cell. After the heat 








Figure 5.3  
Gene construct design for KIX expression. Restriction enzyme sites (NdeI and XhoI) were 
incorporated for cloning purposes. The 6 HIS tag was purposefully placed on the C-terminus for 
purification ease of mClY66 and mIY66 KIX proteins. As codon 66 was changed to the Amber stop 
codon (TAG) for expression of these proteins, only full length protein with the non-canonical 
amino acid properly incorporated would have the 6 HIS tag. This allows us to purify away the 
truncated protein (not containing the HIS tag) from the full length in the initial nickel column 




at 37°C for 1 hour with shaking at 220 rpm. After one hour, approximately 200 µL of the cells 
were plated onto agar plates with appropriate antibiotics (kanamycin for WT KIX and 
chloramphenicol for the codon plus cells), and the plates were placed in a 37°C incubator to grow 
overnight. Colonies were picked from the plates the next day and put in liquid LB (with appropriate 
antibiotics) to confirm plasmid incorporation, and glycerol stocks were made from these starters. 
Several experiments were carried out to optimize the conditions associated with 
incorporation of the non-canonical amino acids. Initially, control experiments with a TAG-GFP 
construct were carried out to test the tRNA-synthetase’s ability to incorporate the meta-
halogenated tyrosine in the given media and temperature conditions (figure 5.4a), and evaluate the 
incorporation efficiency through SDS-PAGE. Once we verified the incorporation, several cell lines 
were tested including pLysS and codon plus, before settling on DE3 which showed the highest 
expression. Throughout this process, various induction OD values were tested (cultures were 
induced at OD600 values ranging from 0.5 – 1.5), as well as expression times. An OD600  ~0.75 and 
a 17-hour expression at 23 °C was found to yield the highest amount of protein. 
For protein expression, WT KIX cells from the glycerol stocks were grown in 2xYT with 
appropriate antibiotics (kanamycin and chloramphenicol) at 37°C while being shaken at 220 rpm 
until the culture reached an OD600 of 0.75. IPTG was then added (to a concentration of 1mM) to 
induce protein expression in the cultures, and the temperature was dropped to 23°C for expression 
over 17 hours. The temperature was dropped to reduce the likelihood of the protein unfolding or 
adopting a non-native structure. After expression, cells were harvested by centrifugation at 7000 




Figure 5.4  
Example protein expression and purification gels. a) Control GFP study done to evaluate efficiency 
of the tRNA-synthetase pair incorporating meta-halo-tyrosine into GFP. Without the non-
canonical amino acid (ncAA) present no full length protein is produced, however expression with 
the ncAA revealed about a 50% incorporation yield. b) Fractions of WT KIX after Ni column 
purification step. Fractions were run on a 15% polyacrylamide gel in order to determine which 
fractions to pool and concentrate for further purification/buffer exchange. c) Final purified WT, 
mClY66, and mIY66 KIX  proteins after gel filtration column showing purity and relative expression 
yields with ncAA.  
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The pET26 plasmid bearing the TAG KIX sequence was transformed into BL21 DE3 cells, 
and this cell line was made competent to allow for a subsequent transformation of the  pDule2-
Mb-ClTyrRSC6 plasmid. Competent cell prep started by making Inoue transformation buffer (55 
mM manganese chloride, 15 mM calcium chloride, 250 mM potassium chloride, 10 mM PIPES 
pH 6.7). A starter culture of the DE3 cells containing the TAG KIX plasmid and kanamycin was  
added to 250 mL of LB. When an OD600 of 0.6 for the cells was reached, the cells were spun down 
at 3900 rpm at 4°C for 10 minutes. The supernatant was subsequently poured off and the pellet 
resuspended in 80 mL of Inoue transformation buffer. This 80 mL of cells in Inoue buffer was 
centrifuged at 3900 rpm at 4°C for 20 minutes and the supernatant poured off again. The pellet 
was resuspended in another 20 mL of Inoue transformation buffer and 1.5 mL of DMSO was 
added. The cells were aliquoted and stored in the -80°C freezer. These cells were then ready to be 
transformed with the plasmid containing the unnatural amino acid incorporation machinery. The  
pDule2-Mb-ClTyrRSC6 plasmid contains the orthogonal Mb tRNACUA and 3-halo-Tyr amino acyl-
tRNA synthetase to allow for incorporation of specifically meta-halogenated tyrosine amino acids. 
The BL21 DE3 cells bearing both the KIX and tRNA/synthetase machinery plasmids were grown 
in LB media with the appropriate antibiotics (kanamycin for the TAG KIX plasmid and 
spectinomycin for the tRNA/synthetase plasmid) for expression at 37°C while being shaken at 220 
rpm. The required non-canonical amino acid (mClY or mIY) was added to a final concentration of 
1mM before beginning expression. When an OD600 of 0.75 was reached, IPTG to 1mM was added 
to induce expression of mClY66 or mIY66 KIX protein. After induction, the cultures were allowed 
to grow for an additional 17 hours at 23°C. After expression, the cells were harvested by 
centrifugation at 7000 rpm for 30 minutes. The supernatant was subsequently decanted, and the 
bacterial pellets stored at -80°C until purification. 
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o 5.3.2 Protein Purification  
The frozen bacterial pellets were resuspended in ~15-20 mL of buffer A (500 mM sodium 
chloride, 50 mM TRIS, and 0.02% sodium azide pH 7.7) and allowed to gently thaw on ice. The 
thawed pellet was lysed by sonication on ice for three 30s intervals on a Branson Sonifier 450 
sonicator (duty cycle of 70%, output control of 7). After cell lysis, the suspension was centrifuged 
at 17000 rpm and 4°C for 45 minutes. The supernatant was then filtered through a 0.45 µm pore 
syringe filter. The filtered lysate was loaded on to the AKTA start FPLC system applying 10% 
buffer B (500 mM sodium chloride, 50 mM TRIS, 0.02% sodium azide, and 500 mM imidazole 
pH 7.7) onto a 5 mL HisTrap HP column. Non-bound protein was washed out with 17% buffer B 
over 3 column volumes. The His-tagged KIX was eluted over a 75-100% buffer B gradient over 5 
column volumes. Fractions thought to contain the protein, according to the chromatogram, were 
run on a 15% polyacrylamide gel (figure 5.4b) and then combined and concentrated at 4°C in a 
10000 MWCO Amicon Ultra Millipore device. The concentrated protein was then loaded onto a 
GE PD MiniTrap G-25 gravity column equilibrated with appropriate buffer specific for DSC or 
CD experiments (figure 5.4c). The DSC buffer was 100 mM Na/K phosphate and 200 mM sodium 
chloride pH 6.2, and the CD buffer was 50 mM TRIS and 150 mM sodium perchlorate pH 6.2. 
After the buffer exchange, the protein was aliquoted and stored in -80°C until needed. 
o 5.3.3 Pdr1p-12mer Peptide Purification  
 
A 12mer peptide with sequence N-EDLYSILWSDVY-C was ordered crude from Biomatik 
and came 57% pure. The lyophilized peptide was resuspended in HPLC Buffer A (0.1% 
trifluoroacetic acid (TFA) and 99.9% water) and purified on a C18 semi-preparative column with 
a gradient between 0.1% TFA in water and 0.1% TFA in acetonitrile. HPLC fractions containing 
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the full-length pure peptide were dried down in a speed vacuum and resuspended in the appropriate 
buffer for the set of experiments. 
o 5.3.4 Differential Scanning Calorimetry  
Protein samples at 1 mg/mL in 100 mM Na/K Phosphate and 200 mM sodium chloride pH 
6.2 were used for DSC experiments. Melting profiles were collected on a TA Instruments Nano 
DSC model 602001 under 3 atm constant pressure. The concentration of at least 1 mg/mL was 
required to obtain sufficient signal-to-noise from the instrument. Samples were set to equilibrate 
for 600s before a heating cycle from 0 – 90°C at a scan rate of 1°C/min followed by a cooling 
cycle to confirm refolding reversibility. A minimum of four replicate experiments were performed 
on each protein. The TM, DHM and DSM values reported are averages from the four scans with a 
standard deviation calculated from the replicates as well. 
Melting data were analyzed and thermodynamic properties determined with NanoAnalyze 
Data Analysis, version 3.6.0, from TA Instruments. All of the scans were background subtracted 
to eliminate heat changes from the buffer over the temperature range. The melting temperatures 
(TM) and melting enthalpies (DHfit) were found by fitting the buffer subtracted and baseline 
corrected data to the two-state scaled model, as the folding/re-folding process is reversible. The 
DHcal was found from the baseline subtracted raw data and compared to the DHfit. One measure of 
“goodness of fit” for the DSC data is found in the DHfit/DHcal ratio. This ratio should be as close 
to 1 as possible, and all of the ratios calculated were in the 0.97-1.01 range. Another value to 
consider is the Aw value. It is a value that scales the data from the DHcal according to the user’s 
concentration and molecular weight input. This value should also be 1, indicating the proper values 
are being used to fit the data. The Aw’s ranged from 0.99-1.07 for all the data. The software 
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automatically calculates a DSM from the DHcal due to the property of DG = 0 at the TM, so DH = 
TDS from the equation DG = DH - TDS. A DSM from the DHfit can be calculated in the same way.  
o 5.3.5 Circular Dichroism Studies 
CD spectra were collected on just the KIX proteins (apo), as well as the KIX protein with 
ligand peptide present to understand the effects the mXY has on the fold of the protein as well 
secondary structural changes that ensue upon binding the peptide. Protein samples at 5 µM were 
prepared in 50 mM TRIS and 150 mM sodium perchlorate pH 6.2. Samples were placed in a 1 mm 
cuvette and at least three scans were collected on each sample. Scans from 190 to 285 nm were 
taken at a rate of 1 nm/sec. The spectra from the buffer was subtracted out of each of these. The 
mean residue ellipticity was calculated for each scan and the averages graphed. The spectra were 
put through the algorithm BeStSel15 to calculate the % helicity. These results correlate with the 
222/208 ratios calculated from the spectra as well. CD experiments of the KIX protein with the 
ligand peptide were also performed in triplicate. Samples of different KIX protein: Pdr1p-12mer 
peptide in molar ratios of 10:1 5:1 2:1 1:1 1:5 and 1:10 were tested to understand how the 
secondary structure of the protein changes as it binds the peptide. The KIX protein was held at a 
constant 5 µM throughout the titration with increasing molar amounts of peptide added. As far as 
analyzing this data, the CD signal from the buffer was subtracted out and the signal from the 
peptide at its concentration was also subtracted out. The Pdr1p-12mer peptide alone looked like a 
classic example of a “random coil.” The 222/208 spectral shifts were monitored throughout the 
titration indicating how the structure of the protein changes in relation to the amount of peptide 
present. All of these spectra were also put into BeStSel15 to calculate the % helicity at each titration 
point as well. 
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o 5.4 Results 
o 5.4.1 Protein Expression with Non-Canonical Amino Acids  
 Expression of WT KIX in 1 L of media typically yields around 2 mL of  20 mg/mL. The 
mClY66 KIX expression normally generates around 1 mL of 10 mg/mL, or about 25% of the WT 
expression amount. The mIY66 KIX expression has a slightly lower yield than the mClY66 KIX at 
about 1 mL of 8 mg/mL (figure 4c). It is fairly common in this field to get around 10% of the WT 
expression level when expressing a protein with a non-canonical amino acid, so the current 
incorporation strategy is surpassing this mark.  
o 5.4.2 Circular Dichroism of Apo KIX Proteins 
 These experiments were done to address if all of the proteins were folding properly with 
the incorporation of the mXY amino acid and maintaining their expected helical rich structure, as 
suggested by NMR and crystallography. The scans of just the purified proteins alone (WT, mClY66, 
and mIY66) (figure 5.5) indicate that all of the proteins maintain their secondary structure as the 
dominating secondary structure is a-helical. The calculated MRE from the raw data was put into 
BeStSel15 and the % helicity calculated with the algorithm revealed the engineered KIX proteins 
to have as much as 10% higher helicity. This may indicate that the 3-helix bundle of the protein is 
tighter, or the partially unfolded helix (a1)16 in the structure has folded with mXY present.  
o 5.4.3 Differential Scanning Calorimetry to Assess KIX Stability 
 Once we determined the mXY were not disrupting the proteins fold significantly, DSC 
studies were carried out to assess the engineered proteins thermal stability and understand if the 
halogen was providing any enthalpic stability. Prior to carrying out the data analysis described 
above (5.3.4), we needed to address whether the yeast KIX domain adopts a simple two state 




Contruct BeStSel % Helicity 
WT KIX 66.9 
mClY66 KIX 72.6 
mIY66 KIX 80.8 
 
Figure 5.5  
CD spectra of Apo WT, mClY66 and mIY66 KIX proteins. When the Mean Residue Ellipticity 
calculated from the spectra was put through BeStSel, the % helicity calculated increased from the 
WT to the mIY66 KIX protein.  
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do this, we carried out the normal heating scan on the WT protein, and then performed a cooling 
scan from 90°C - 0°C at 1°C/minute where the protein was allowed to cool and refold. Following 
this cooling scan, we did another heating scan from 0°C - 90°C at 1°C/minute. The area under each 
heating (2 of them) and cooling scan (1) was calculated as it represents the relative enthalpy of 
unfolding or folding. To assume a simple two-state unfolding-folding mechanism, the enthalpy of 
folding and refolding should be the same 17. However, because not 100% of the protein refolds 
properly, the relative enthalpies need to be scaled according to the amount of protein that refolded. 
In looking at the two heating scans, the enthalpy of the second heating scan is ~77% of the initial 
heating scan, implying ~77% of the protein refolded properly. The folding enthalpy was then 
scaled to the amount of protein that refolded (77%), and the difference between the unfolding and 
folding enthalpies differ by only 0.3 kJ/mol, suggesting the yeast KIX follows a simple two-state 
folding-refolding mechanism (figure 5.6). Troilo et al. also found KIX to adopt a simple two-state 
fold-refolding mechanism through stopped-flow and equilibrium experiments 16.  
 The melting profiles from all three proteins revealed an increase in TM with the addition of 
the unnatural amino acid (figure 5.7). The KIX domain became ~3°C more stable than WT with 
the addition of mClY66 and gained another ~2°C (so 5°C more stable than WT) with the addition 
of mIY66 (table in figure 5.7). This alone tells us that the protein has become more thermally stable, 
but taking a closer look at the enthalpy (DH) and entropy (DS) will help us discern if the amino 
acid incorporated is forming a stabilizing bond, or just acting as a hydrophobic-space filling 
molecule in this context. In looking at the DHM, both engineered proteins have gained a couple 
kcal/mol of energy at the TM, with the mClY66 KIX gaining ~2 kcal/mol, and the mIY66 KIX gaining 




Figure 5.6  
DSC analysis to verify the KIX domain has a simple two-state unfolding-refolding behavior. The 
Tmax’s for the two melting profiles are almost identical, and the calculated % refolded protein from 




Figure 5.7  
The graph shows representative DSC melting profile for WT, mClY and mIY KIX proteins. A clear 
shift in the TM can be seen from these profiles. The table displays the average and standard 
deviation of the thermodynamic information calculated from the four replicate DSC scans done on 
each protein.   
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TDS as DG  at the TM is 0. This increase in DHM corresponds to an increase in DSM of ~4.5 cal/mol 
* K for the mClY66 KIX, and an increase of ~9.2 cal/mol * K for the mIY66 KIX.   
o 5.4.4. CD Titration of KIX with Binding Partner Pdr1p-12mer 
A CD titration was also carried out on the WT and mClY66 KIX proteins to ask if the 
engineered proteins can bind Pdr1p-12mer, and what (if any) structural changes ensue upon 
binding. Over the course of the titration an increase in helicity is noted by an increase in the  
ellipticity at 222 nm /208 nm ratio. The 222/208 changes from a ratio of 0.97 to 1.03 for the WT 
KIX and 1.02 to 1.06 for the mClY66 KIX. Furthermore, this ~0.04 increase in 222/208 ratio occurs 
at a lower concentration of Pdr1p-12mer present for mClY66 KIX compared to WT (figure 5.8). 
o 5.5 Discussion and Conclusions 
In this preliminary in vitro work on yeast KIX, we see through non-canonical amino acid 
incorporation, we have not significantly affected the fold of the protein with the incorporation of 
mXY at position 66, however, we have significantly increased the thermal stability of yeast KIX 
with this engineering strategy. The two engineered proteins mClY66 and mIY66 KIX both have 
higher significantly higher melting temperatures (TM) and melting enthalpies (DHM) compared to 
WT. We have also seen with the CD titration with Pdr1p-12mer, that mClY66 KIX potentially binds 
the peptide at a “higher affinity” compared to WT KIX as noted by a larger shift in the 222 nm/208 
nm ratio at lower concentrations of Pdr1p-12mer. In our previous engineering efforts of T4L with 
meta- chlorotyrosine, we only slightly increased the melting temperature (~1°C) of the protein. 
Herein, we have shown how impactful HBeXB engineering efforts are in terms of stabilizing a 
protein with an intrinsically disordered region. The addition of the single chlorine or iodine atom 
has increased the TM by 2 and 3 °C respectively and allowed the protein to gain an additional 2-4 




Figure 5.8  
a) Shows graphs of the CD spectra titration study. A slight change can be seen as more Pdr1p-
12mer is added to the protein. b) A graph showing the change in 222/208 ratio vs. the concentration 
of Pdr1p present throughout the titration, and a table showing the % Helicity as calculated from 
BeStSel. The mClY KIX approaches a 222/208 ratio of 1 at a much lower concentration of Pdr1p 
present compared to WT KIX. The mClY KIX also has a higher helicity throughout the titration 
compared to WT KIX.  
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While these results indicate the increased stability and binding activity of the protein are 
due to the HBeXB bond, without a definitive crystal structure, it is hard to say if the halogen on 
the meta-halotyrosine is making a halogen bond and, moreover, if it is being enhanced by the 
hydroxyl group. In looking at the ESP maps of 2-chlorophenol and 2-iodophenol, we see the 
neutral point on the surface of the molecule extends to 150° and 125° respectively when the 
hydrogen is pointed towards the negative annulus of the halogen, which suggests acceptor atoms 
can approach the halogen at angles as low as those, and still be participating in an X-bond (figure 
5.9). As the protein has a slightly unfolded region, the incorporation of the meta-halotyrosines 
could slightly rearrange atoms in the helical bundle making it hard to predict where the halogen 
aligns. However, we can model meta-halotyrosines into existing KIX structures to perhaps get an 
idea of how the halogen could be behaving. 
In modeling meta-chlorotyrosine into an NMR structure of yeast KIX (PDB: 2k0n), we see 
the chlorine could have a q1 as high as 162° with an interaction distance to the oxygen of 3.0 Å, 
which is ~92% of the van der Waal radii (figure 5.10). We have carried out some theoretical 
quantum mechanical calculations on small-molecule mimics, 2-halophenols interacting with N-
methylacetamide (NMA), at various distances and angles to better understand the energy profile. 
These simplified calculations show when 2-chlorophenol interacts with NMA at a q1 of 160° and 
a distance of 3.0 Å to the acceptor atom, the energy of the interaction is estimated to be 1.3 
kcal/mol. The energy of the intramolecular H-bond to the halogen is estimated to be ~1.85 kcal/mol 
from our previous T4L engineering efforts11. Together, these bonds would provide ~3.2 kcal/mol  
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Figure 5.9  
Electrostatic potential maps showing the theoretical neutral point of the s-hole on 2-chlorophenol 
and 2-iodophenol. These angles represent the maximum angle of approach an acceptor molecule 





Figure 5.10  
NMR structure of yeast KIX (PDB 2k0n) with conserved Y66 and a modeled in mClY66. The 
chlorine could be making a very strong X-bond with a distance of 3.1 Å and a q1 of 160°. The 
quantum mechanical calculations were carried out based on this modeled geometry.  
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in enthalpy. As this is slightly higher than we see in the DSC results (2 kcal/mol), perhaps the 
chlorine is positioned at a lower q1 approach angle or is interacting with an acceptor atom at a 
longer distance. An alternative interpretation could be that the chlorine is at this modeled geometry 
(160° and 3.0 Å), but, the hydrogen is not pointing towards the chlorine, and a true HBeXB is not 
forming. In this scenario, the modest increase of 1.3 kcal/mol aligns well with a simple chlorine 
XB. Carrying out the same calculations on 2-iodophenol at a q1 of 160° and a distance of 2.6 Å to 
the oxygen in NMA reveals an interaction energy of ~1.45 kcal/mol. Adding in the energy of the 
intramolecular H-bond would make the overall energy ~3.3 kcal/mol, which aligns well with our 
DSC results. These hypotheses seem to support the enthalpic terms obtained from the DSC 
measurements, however, getting crystal structures of the proteins will resolve any speculation 
about the placement of the halogen and the existence of the HBeXB.  
The CD titration showed us that the mClY66 KIX increases its structural helicity in the 
presence of a lower concentration of Pdr1p-12mer peptide compared to WT KIX. While we were 
not able to calculated a Kd from this titration, the shift in the spectra is preliminary evidence of an 
increased binding affinity13. Perhaps the stabilized KIX is locked in a conformation more 
conducive to binding this partner. Or, perhaps, the meta-halo-tyrosine helped fold a1 in the 
structure in a way that allows for a tighter interaction to take place. This assay at the very least 
shows mClY66 KIX has not lost its ability to interact with Pdr1—12mer. The result will need to be 
confirmed and compared to a titration with mIY66 KIX to further evaluate how the different 
halogens are affecting potential binding activity. Applying this increase in affinity in an in vivo 
context, we start to think about how this could be altering the protein’s function. More often than 
not in the cell, proteins have particular binding affinities to ligands to carry out tasks accordingly. 
Low binding affinities might indicate the need for high turnover on a particular reaction as the koff  
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could be high. Contrary, high binding affinities are usually associated with very low koff  rates.  
Since the KIX protein binds the Pdr1p protein as a means to help turn on transcription of drug 
efflux genes5 (figure 5.1) altering this behavior could have vast effects on these genes’ expression 
levels. The increased binding affinity could prevent KIX from releasing Pdr1p, possibly 
augmenting transcription of the drug efflux genes. Alternatively, the increased affinity could 
prevent KIX’s release from Pdr1p potentially inhibiting or delaying the transcription of the genes, 
thereby affecting the genes’ downstream influences. Perhaps the increased binding affinity of KIX 
to Pdr1p will prevent the export of “toxic drugs” allowing the anti-fungals or “toxic drugs” to be 
useful again.  
The very preliminary results from this study are promising and exciting and have raised 
new questions. One key aspect of this study that is most exciting for the field is the impact a single 
atom can have in terms of stabilizing a protein with an intrinsically disordered region, and how the 
slight structural change can impact function. These initial findings suggest the incorporation of 
meta-halotyrosine into a protein with an intrinsically disordered region can aid its enthalpic 
stability, with a tunable aspect in terms of halogen choice. This should aid those interested in 
stabilizing aggregation-prone proteins that are associated with disease states 18,19, and perhaps be 
a valuable strategy in terms of designing more stable biologic therapeutics . It will be interesting 
to discover with the in vivo studies how the engineered KIX proteins binding partners vary, and 
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CHAPTER 6: CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
o 6.1 Summary  
The work herein has looked at the relationship between hydrogen and halogen bonds from 
a inter and intramolecular level. Through protein engineering efforts, we have shown how the 
bonds are similar in terms of specifying capabilities. We have shown how they can act 
synergistically and enhance one another in an intramolecular environment. And, we have shown 
how the bonds can differ from an enthalpy – entropy standpoint. The work will add to the growing 
fundamental knowledge of the structure-energy relationship X-bonds possess in biomolecular 
systems. This will be valuable to pharmaceutical companies looking to incorporate halogens into 
peptide or protein therapeutics. But also, the peptide (GCN4) and protein (yeast KIX) systems we 
selected to work with are biologically relevant. The detailed work on the GCN4 peptide could 
become a probe for transcription as the designed H- or X-bond-bearing peptide could act as a 
transcriptional regulator when binding endogenous GCN4. And, the HBeXB stabilization efforts 
of yeast KIX will aid those studying how to stabilize aggregation-prone proteins.  
The next step for both of these projects is to study them in an in vivo environment. This 
would allow for the designed peptide from GCN4 to act as potential transcription sensing probe, 
and will allow us to investigate the change in cellular regulation pathways derived from stabilized 
KIX. 
o 6.2 A Complex Interplay Exists Between Hydrogen and Halogen Bonds 
In Chapter 2 we delved into the relationship between hydrogen and halogen bonds seen 
from a biomolecular perspective. We broke their relationship into 3 main categories 1) competition 
between H and X-bonds in biological systems, 2) substitution of an X-bond for an H-bond and 
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how that affects the system, and 3) the orthogonal or synergistic relationship seen between the 
bonds. It’s no trivial task predicting how the bonds may complement or compete against one 
another, but chemists and biochemists alike should consider these relations in molecular design. 
As more X-bond engineering work is carried out, more defined directives can be established for 
molecular design strategies. We kept the concepts learned from this review in mind while carrying 
out our own protein engineering endeavors discussed in Chapter 4 and 5.   
o 6.3 Hydrogen Bond Enhanced Halogen Bonds Exist in Not Only Biomolecular Systems 
Chapter 3 describes the opportune discovery of the hydrogen bond enhanced halogen bond 
in two unique systems. This study shows the wide application of the HBeXB as it was discovered 
in an organic small-molecule system as well as a protein system. The HBeXB theory suggests the 
hydroxyl is acting as an electron-withdrawing group as it enhances the size of the s-hole, so 
quantum mechanical calculations were carried out to better understand this. As OH is typically 
thought of as an electron-donating group, the charges on the carbon atoms in phenol reflect this 
for the ortho- and para- carbons (negatively charged), but, the meta- position carbon is positively 
charged reflecting the electron-withdrawing ability of the hydroxyl. A survey of the CSD and PDB 
was carried out looking for the existence of HBeXB’s in small molecule and biological systems. 
As many hits appeared, it seems the Berryman and Ho labs are just the first to experimentally 
recognize the interaction and its potential impact on the halogen bonding field. 
o 6.4 Halogen Bonds Can Behave as a Specifying Protein-Protein Interaction 
Chapter 4 discusses how engineering an H-bond or X-bond donor into the GCN4 N16A 
coiled coil sequence aids in the assembly of a specific heterotrimer complex. We showed the 
engineered electrostatic interactions are capable of assembling the specific heterotrimer complex 
across a range of concentrations (signifying their high affinity), unlike the non-specific 
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hydrophobic molecules also tested. This study points at the potential the H- and X-bond peptide 
possesses as a transcriptional inhibitor of GCN4, while also revealing how powerful the designed 
electrostatic interaction could be for other peptide assemblies. This study opens a up a new “knobs-
in-holes” realm for coiled-coils as the concepts could be applied to finely tune oligomerization rate 
and behavior.  
o 6.5 Hydrogen Bond Enhanced Halogen Bonds Can Increase Stability in KIX 
In Chapter 5 we incorporated mXY into yeast KIX to better understand how the potential 
HBeXB could impact this protein’s structure and function in vitro. We found the mXY did not 
significantly affect KIX’s secondary structure from CD, but it did signifigantly increase its thermal 
stability. We do not know for sure whether a true HBeXB bond is forming in the structure. We are 
working on crystallizing KIX, which will give us more information about the placement of the 
halogen. The CD titration revealed a slight increase in helicity at lower Pdr1p-12mer 
concentrations for the mClY66 KIX as compared to WT, perhaps indicting the mClY66 binds this 
peptide at a higher affinity. As KIX’s intrinsically disordered region partially defines its function, 
investigating how this stabilized version of KIX will impact its function and influence overall 
cellular regulation from an in vivo standpoint will be interesting to look at next. 
o 6.6 Future Directions 
For GCN4’s use as a sensing probe, or understanding how stabilized KIX modifies cellular 
function, the next steps for the work depicted in Chapters 4 and 5 would be to evaluate the proteins 
in vivo. The in vivo characterization will allow for the application of the designed GCN4 peptide 
as a sensing probe. We could tag endogenous GCN4 and load the designed GCN4 peptide into 
yeast cells looking for colocalization among the proteins. We could also set-up a reporter gene 
(lacZ and X-Gal) assay in yeast to monitor how the designed GCN4 peptide could act as a 
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transcriptional switch. We hypothesize in the absence of the designed peptide, the yeasts cells 
would express lacZ and turn blue. Upon loading in the peptide, endogenous GCN4 may be 
inhibited by the peptide and not be able to properly promote expression of lacZ, leaving the cells 
opaque. These in vivo studies could show how useful the designed H-bond or X-bond-specifying 
peptide could be as a transcriptional probe. 
Expressing the KIX mutants in yeast cells (which could involve eukaryotic unnatural 
amino acid incorporation) and carrying out RNA-seq studies would allow us to tease out which 
genes get up/down-regulated as a result of the presence of mXY KIX. To gauge how KIX is 
modifying cellular pathways, we must take a look at the genomic level, and this type of experiment 
will help us determine which cellular pathways are potentially distressed or unaffected. As yeast 
KIX is part of the pleiotropic drug response pathway, we could look at those genes specifically to 
glean insights on how KIX is binding with partners in the pathway. A more detailed understanding 
of these interactions could be useful, as KIX is a clinical target.  
Overall, this dissertation has looked at how useful X-bonds can be for biological 
engineering efforts. Compared to H-bonds, they have unique properties that will be advantageous 
for exploitation in biologically derived therapeutics, increasing enzyme activity, designing high 






Supplemental Figure 1.  
DSC melting profiles from all of the constructs. The MeF16 and IF16 profiles are wider than the 
trimer melting profile and shifted over another 4 °C (FWHM is ~25 °C). When the data were fit 
to one simple two-state model (as all of the other constructs were), the residual around the fit was 





Supplemental Figure 2.  
Homodimer presence in IF16 melting profile. The buffer and baseline subtracted A16 and TFIF16 
data were subtracted from the IF16 to indicate the presence of an IF16 homodimer.  
 
